<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="hwp">eLife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">22706</article-id><article-id pub-id-type="doi">10.7554/eLife.22706</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Developmental Biology</subject></subj-group></article-categories><title-group><article-title>A metabolic switch controls intestinal differentiation downstream of <italic>Adenomatous</italic> polyposis coli (APC)</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-72207"><name><surname>Sandoval</surname><given-names>Imelda T</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-5400-5611</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-73838"><name><surname>Delacruz</surname><given-names>Richard Glenn C</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-73839"><name><surname>Miller</surname><given-names>Braden N</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-73840"><name><surname>Hill</surname><given-names>Shauna</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-73841"><name><surname>Olson</surname><given-names>Kristofor A</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-83431"><name><surname>Gabriel</surname><given-names>Ana E</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-83432"><name><surname>Boyd</surname><given-names>Kevin</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-73842"><name><surname>Satterfield</surname><given-names>Christeena</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-37104"><name><surname>Van Remmen</surname><given-names>Holly</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-16102"><name><surname>Rutter</surname><given-names>Jared</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2710-9765</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-73837"><name><surname>Jones</surname><given-names>David A</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2391-779X</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-3"/><xref ref-type="other" rid="par-4"/><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution content-type="dept">Functional and Chemical Genomics</institution>, <institution>Oklahoma Medical Research Foundation</institution>, <addr-line><named-content content-type="city">Oklahoma City</named-content></addr-line>, <country>United States</country></aff><aff id="aff2"><label>2</label><institution content-type="dept">Aging and Metabolism Research Program</institution>, <institution>Oklahoma Medical Research Foundation</institution>, <addr-line><named-content content-type="city">Oklahoma City</named-content></addr-line>, <country>United States</country></aff><aff id="aff3"><label>3</label><institution content-type="dept">Department of Cellular and Structural Biology</institution>, <institution>University of Texas Health Science Center at San Antonio</institution>, <addr-line><named-content content-type="city">San Antonio</named-content></addr-line>, <country>United States</country></aff><aff id="aff4"><label>4</label><institution content-type="dept">Department of Biochemistry</institution>, <institution>University of Utah School of Medicine</institution>, <addr-line><named-content content-type="city">Salt Lake City</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Krumlauf</surname><given-names>Robb</given-names></name><role>Reviewing editor</role><aff><institution>Stowers Institute for Medical Research</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><email>david-jones@omrf.org</email></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>11</day><month>04</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>6</volume><elocation-id>e22706</elocation-id><history><date date-type="received"><day>15</day><month>11</month><year>2016</year></date><date date-type="accepted"><day>17</day><month>03</month><year>2017</year></date></history><permissions><copyright-statement>© 2017, Sandoval et al</copyright-statement><copyright-year>2017</copyright-year><copyright-holder>Sandoval et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-22706-v1.pdf"/><abstract><object-id pub-id-type="doi">10.7554/eLife.22706.001</object-id><p>Elucidating signaling pathways that regulate cellular metabolism is essential for a better understanding of normal development and tumorigenesis. Recent studies have shown that <italic>mitochondrial pyruvate carrier 1 (MPC1)</italic>, a crucial player in pyruvate metabolism, is downregulated in colon adenocarcinomas. Utilizing zebrafish to examine the genetic relationship between <italic>MPC1</italic> and <italic>Adenomatous polyposis coli (APC),</italic> a key tumor suppressor in colorectal cancer, we found that <italic>apc</italic> controls the levels of <italic>mpc1</italic> and that knock down of <italic>mpc1</italic> recapitulates phenotypes of impaired <italic>apc</italic> function including failed intestinal differentiation. Exogenous human <italic>MPC1 RNA</italic> rescued failed intestinal differentiation in zebrafish models of <italic>apc</italic> deficiency. Our data demonstrate a novel role for <italic>apc</italic> in pyruvate metabolism and that pyruvate metabolism dictates intestinal cell fate and differentiation decisions downstream of <italic>apc</italic>.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.22706.001">http://dx.doi.org/10.7554/eLife.22706.001</ext-link></p></abstract><abstract abstract-type="executive-summary"><object-id pub-id-type="doi">10.7554/eLife.22706.002</object-id><title>eLife digest</title><p>Colon cancer remains an important problem in healthcare. Cancer researchers are looking for new ways to detect the disease earlier and treat it more effectively. This is challenging because many of the genetic and molecular causes of colon cancer are still poorly understood. Mutations in the gene that encodes a protein called APC are one of the major causes of the disease. The APC protein normally keeps cells from growing and dividing too fast or in an uncontrolled way and is hence referred to as a tumor suppressor. For example, APC induces stem cells in the intestine to develop into specialized cells that keep the gut working normally. Mutations in tumor suppressor genes are common in many cancers.</p><p>Other research has shown that cancer cells must reprogram their own metabolism – in other words, all the chemical processes that keep the cell alive – to meet the demands of proliferating rapidly. In particular, recent studies reveal that colon cancer cells produce less of a protein called mpc1, which is involved in metabolism. These discoveries raised the following questions: does APC have an additional role in maintaining normal metabolism in cells by controlling how much mpc1 is produced? Do mutations in the gene for APC lead to colon cancer because they alter the cell’s metabolism?</p><p>Sandoval et al. have now discovered a connection between APC and changes in cancer cells that help them to adapt to a new metabolic program. Experiments with zebrafish – a model animal that is now commonly used in the field of cancer biology – showed that APC acts via mpc1 to regulate how the cell uses energy. This regulation goes awry in colon cells that have abnormal APC activity; however, restoring the cell’s metabolism back to normal was enough to induce cells in the intestine to develop properly.</p><p>Together, these findings suggest that restoring the normal balance of energy production in colon cancer cells may be an effective way to make the cells behave normally. This hypothesis remains to be tested and, if confirmed, further studies will be needed to determine whether it will lead to new treatments for colon cancer in humans.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.22706.002">http://dx.doi.org/10.7554/eLife.22706.002</ext-link></p></abstract><kwd-group kwd-group-type="author-keywords"><title>Author Keywords</title><kwd>adenomatous polyposis coli</kwd><kwd>mitochondrial pyruvate carrier</kwd><kwd>zebrafish</kwd><kwd>pyruvate metabolism</kwd><kwd>intestinal differentiation</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research Organism</title><kwd>Zebrafish</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>RO1 CA116468NIH</award-id><principal-award-recipient><name><surname>Jones</surname><given-names>David A</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100001384</institution-id><institution>Samuel Waxman Cancer Research Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Jones</surname><given-names>David A</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100008907</institution-id><institution>Oklahoma Medical Research Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Jones</surname><given-names>David A</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution>Oklahoma Center for Adult Stem Cell Research</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Jones</surname><given-names>David A</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>elife-xml-version</meta-name><meta-value>2.5</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>The tumor suppressor APC regulates a metabolic program that drives normal intestinal differentiation in zebrafish.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Mutations in the adenomatous polyposis coli (<italic>APC)</italic> gene are responsible for Familial Adenomatous Polyposis (FAP), a genetic predisposition to colorectal cancer, and are also found in the majority of sporadic colonic tumors (<xref ref-type="bibr" rid="bib14">Fearnhead et al., 2001</xref>). Critical roles for APC in colon carcinogenesis are attributed to its ability to negatively regulate the proliferative consequences of Wnt signaling through degradation of β-catenin, and maintain normal intestinal differentiation by controlling the biosynthesis of retinoic acid (RA) (<xref ref-type="bibr" rid="bib21">Jette et al., 2004</xref>; <xref ref-type="bibr" rid="bib30">Nadauld et al., 2006a</xref>, <xref ref-type="bibr" rid="bib28">2004</xref>, <xref ref-type="bibr" rid="bib29">2005</xref>; <xref ref-type="bibr" rid="bib33">Rai et al., 2010</xref>; <xref ref-type="bibr" rid="bib39">Schneikert et al., 2007</xref>; <xref ref-type="bibr" rid="bib40">Shelton et al., 2006</xref>). Although tremendous progress has been made in understanding the role of APC, its full battery of functions continue to expand.</p><p>Altered energy metabolism is an emerging hallmark in cancer (<xref ref-type="bibr" rid="bib18">Hanahan and Weinberg, 2011</xref>). The observation that cancer cells produce energy to support cell growth and proliferation differently than normal cells is known as the Warburg effect, and refers to neoplastic cells favoring aerobic glycolysis, even in the presence of ample oxygen (<xref ref-type="bibr" rid="bib45">Vander Heiden et al., 2009</xref>; <xref ref-type="bibr" rid="bib46">Warburg, 1956</xref>). One of the major molecular mechanisms contributing to Warburg effect is mitochondrial dysfunction through impaired pyruvate metabolism (<xref ref-type="bibr" rid="bib11">Diaz-Ruiz et al., 2011</xref>).</p><p>Pyruvate lies at the junction of glycolysis and the tricarboxylic acid (TCA) cycle. Contingent on the metabolic needs of the cell, pyruvate can be transported into the mitochondria, and through the action mainly of pyruvate dehydrogenase (PDH), it can be used to drive ATP production and generate building blocks for macromolecule biosynthesis through oxidative phosphorylation. Alternatively, pyruvate can be converted to lactate via lactate dehydrogenase (LDH) and exported out of the cell. Aberrations in genes involved in pyruvate metabolism and transport have been reported in human diseases, particularly in cancer (<xref ref-type="bibr" rid="bib17">Gray et al., 2014</xref>). For example, <italic>monocarboxylate transporter 4 (MCT4)</italic> and <italic>LDHA</italic> are overexpressed in cancer (<xref ref-type="bibr" rid="bib22">Kim et al., 2013</xref>; <xref ref-type="bibr" rid="bib34">Rong et al., 2013</xref>). An isoform of <italic>pyruvate kinase 2 (PKM2)</italic> is preferentially expressed in numerous cancer types including pancreatic, colon and lung, and has been shown to promote aerobic glycolysis in HeLa cells by functioning as a transcriptional coactivator for HIF-1 (<xref ref-type="bibr" rid="bib7">Cerwenka et al., 1999</xref>; <xref ref-type="bibr" rid="bib9">Christofk et al., 2008</xref>; <xref ref-type="bibr" rid="bib23">Luo and Semenza, 2011</xref>; <xref ref-type="bibr" rid="bib38">Schneider et al., 2002</xref>; <xref ref-type="bibr" rid="bib49">Yeh et al., 2008</xref>). Restoration of the pyruvate dehydrogenase complex activity through inhibition of pyruvate dehydrogenase kinase 1 (PDK1) in head and neck squamous cell carcinoma cell lines led to reduced HIF-1a expression and tumor growth (<xref ref-type="bibr" rid="bib25">McFate et al., 2008</xref>).</p><p>The recently identified mitochondrial pyruvate carrier subunit <italic>MPC1</italic> is part of the MPC complex that is responsible for the uptake of pyruvate into the inner mitochondrial matrix (<xref ref-type="bibr" rid="bib5">Bricker et al., 2012</xref>; <xref ref-type="bibr" rid="bib19">Herzig et al., 2012</xref>). Recent work has revealed that <italic>MPC1</italic> is downregulated in various human cancers and that this correlates with poor survival (<xref ref-type="bibr" rid="bib37">Schell et al., 2014</xref>). Consistent with a causative role in tumorigenesis, re-expression of MPC1 repressed the Warburg effect in colon cancer cell lines (<xref ref-type="bibr" rid="bib37">Schell et al., 2014</xref>). It is not clear how MPC1 is regulated or how its activities relate to the known genetic events that contribute to colon cancer development. Given the potential role for MPC1 in colorectal cancer and the importance of APC mutation, we investigated the mechanistic relationship between the mutational status of <italic>apc</italic> and <italic>mpc1</italic>. Herein, we report that <italic>apc</italic> regulates pyruvate metabolism by controlling the levels of <italic>mpc1</italic> via RA. Further, <italic>mpc1</italic> is required and sufficient for initiating normal intestinal differentiation downstream of <italic>apc</italic>. Our findings strongly suggest that changes in metabolic profile can drive cell fate and differentiation decisions.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title><italic>mpc1</italic> and <italic>mpc2</italic> are downregulated in <italic>apc</italic>-deficient zebrafish</title><p>To investigate the relationship between <italic>apc</italic> and <italic>mpc</italic>, we utilized the <italic>apc<sup>mcr</sup> </italic>zebrafish, which is homozygous for a truncating mutation in the Mutation Cluster Region (MCR) of <italic>apc</italic> and similar to what is found in human colon tumors (<xref ref-type="bibr" rid="bib20">Hurlstone et al., 2003</xref>; <xref ref-type="bibr" rid="bib26">Miyoshi et al., 1992a</xref>, <xref ref-type="bibr" rid="bib27">1992b</xref>). In parallel, we also knocked down the expression of <italic>apc</italic> in wild type (WT) embryos using antisense morpholino (<italic>apc</italic> mo) (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). Evaluating gene expression of <italic>mpc1</italic> and <italic>mpc2</italic> by qRT-PCR, we found that both genes were significantly downregulated in <italic>apc<sup>mcr</sup></italic> and <italic>apc</italic> mo embryos compared to WT/het siblings and control mo, respectively (<xref ref-type="fig" rid="fig1">Figure 1A,B</xref>). This was confirmed by whole mount in situ hybridization for <italic>mpc1</italic> and <italic>mpc2</italic> (<xref ref-type="fig" rid="fig1">Figure 1C,D</xref>). Additional in situ analyses for <italic>mpc1</italic> and <italic>mpc2</italic> in WT embryos revealed staining in the head, eyes, vasculature and somites at 24–48 hr post-fertilization (hpf) (<xref ref-type="fig" rid="fig1">Figure 1E</xref>). At later time points, expression in the pectoral fin buds, liver and gut emerged (<xref ref-type="fig" rid="fig1">Figure 1E</xref>). Cross sections of 72 hpf WT embryos previously probed with <italic>mpc1</italic> and <italic>mpc2</italic> confirmed gut expression for both genes (black arrows) (<xref ref-type="fig" rid="fig1">Figure 1F</xref>).<fig-group><fig id="fig1" position="float"><object-id pub-id-type="doi">10.7554/eLife.22706.003</object-id><label>Figure 1.</label><caption><title><italic>mpc1</italic> and <italic>mpc2</italic> are downregulated in <italic>apc<sup>mcr</sup></italic> and <italic>apc</italic> morphant embryos.</title><p>(<bold>A</bold>,<bold>B</bold>) Quantitative RT-PCR analysis of <italic>mpc1</italic> and <italic>mpc2</italic> gene expression in <italic>apc<sup>mcr</sup></italic> (<bold>A</bold>) and <italic>apc</italic> mo (<bold>B</bold>) embryos. Values represent mean ± SD. Graph shown above is representative of at least three independent experiments. Statistical significance was analyzed using unpaired t-test. (<bold>C</bold>,<bold>D</bold>) Whole mount in situ hybridization for <italic>mpc1</italic> and <italic>mpc2</italic> in 72 hpf <italic>apc<sup>mcr</sup></italic> (<bold>C</bold>) and <italic>apc</italic> mo (<bold>D</bold>) embryos. (<bold>E</bold>) Whole mount in situ hybridization for <italic>mpc1</italic> and <italic>mpc2</italic> in wild type (WT) embryos. head (h), eyes (e), somite (som), vasculature (vas), gut (g), liver (l). (<bold>F</bold>) Cross sections from 96 hpf WT embryos probed with either <italic>mpc1</italic> or <italic>mpc2</italic> confirmed gut-specific expression of both genes. See also <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.22706.003">http://dx.doi.org/10.7554/eLife.22706.003</ext-link></p><p> <supplementary-material id="SD1-data"><object-id pub-id-type="doi">10.7554/eLife.22706.004</object-id><label>Figure 1—source data 1.</label><caption><title>Fold change calculations for <xref ref-type="fig" rid="fig1">Figure 1A,B</xref></title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.22706.004">http://dx.doi.org/10.7554/eLife.22706.004</ext-link></p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-22706-fig1-data1-v1.xlsx"/></supplementary-material> </p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-22706-fig1-v1"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.22706.005</object-id><label>Figure 1—figure supplement 1.</label><caption><title>PCR analysis confirming <italic>apc</italic> knockdown.</title><p>cDNA from 48 hpf embryos injected with either control (cont mo) or <italic>apc</italic> morpholino (<italic>apc</italic> mo) was used to amplify a 264 bp band corresponding to <italic>apc</italic> WT. A negative control with no reverse transcriptase (-) was also included. Amplification of 18s served as control for input cDNA (67 bp).</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.22706.005">http://dx.doi.org/10.7554/eLife.22706.005</ext-link></p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-22706-fig1-figsupp1-v1"/></fig></fig-group></p></sec><sec id="s2-2"><title>Knock down of <italic>mpc1</italic> phenocopies <italic>apc</italic> knock down</title><p>Previous studies have established phenotypes associated with impaired <italic>apc</italic> function in the developing zebrafish including malformation of the gut, eyes, pancreas and jaw, arrested fin buds and failed heart looping (<xref ref-type="bibr" rid="bib28">Nadauld et al., 2004</xref>; <xref ref-type="bibr" rid="bib20">Hurlstone et al., 2003</xref>; <xref ref-type="bibr" rid="bib31">Nadauld et al., 2006b</xref>). To determine whether loss of <italic>mpc1</italic> would recapitulate morphological defects related to <italic>apc</italic> deficiency, we knocked down the expression of <italic>mpc1</italic> in WT embryos with a splice-blocking morpholino which we confirmed by PCR (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>). Microinjection of 0.75 mM <italic>mpc1</italic> morpholino into WT embryos at the one- to two-cell stage resulted in about 87% of injected embryos appearing morphant (n = 228) (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>). Consistent with downregulation of <italic>mpc1</italic> in <italic>apc<sup>mcr</sup></italic>, <italic>mpc1</italic> morphants (<italic>mpc1</italic> mo) exhibited a range of phenotypes consisting of smaller head and eyes, enlarged hindbrain vesicle (black arrows), pericardial edema, body curvature, and loss of pectoral fins (blue arrows) (<xref ref-type="fig" rid="fig2">Figure 2A</xref>).<fig-group><fig id="fig2" position="float"><object-id pub-id-type="doi">10.7554/eLife.22706.006</object-id><label>Figure 2.</label><caption><title>Knock down of <italic>mpc1</italic> expression phenocopies loss of <italic>apc</italic>.</title><p>(<bold>A</bold>) Gross phenotype associated with <italic>mpc1</italic> knock down. (<bold>B</bold>) Whole mount in situ hybridization analysis for organ-specific markers in <italic>mpc1</italic> mo. Alcian blue staining revealed improper cartilage development (*) and confirmed loss of pectoral fins in <italic>mpc1</italic> mo. pectoral fin bud (pfb), heart (h), gut (g), pancreas (p). (<bold>C</bold>) Cross section of the eye and gut from control or <italic>mpc1</italic> mo. Prior to sectioning, embryos were previously stained with eye and gut-specific markers, <italic>irbp</italic> (red arrow) and <italic>fabp2</italic> (black arrow), respectively. (<bold>D</bold>) Co-injection with human <italic>MPC1</italic> RNA led to increased percentage of <italic>mpc1</italic> mo with normal pectoral fins as determined by in situ staining for <italic>idi1</italic>. Statistical significance was analyzed using Fisher’s exact test. See also <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplements 1</xref>, <xref ref-type="fig" rid="fig2s2">2</xref>.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.22706.006">http://dx.doi.org/10.7554/eLife.22706.006</ext-link></p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-22706-fig2-v1"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.22706.007</object-id><label>Figure 2—figure supplement 1.</label><caption><title><italic>mpc1</italic> morphant phenotype is rescued by human <italic>MPC1</italic> RNA.</title><p>(<bold>A</bold>) PCR analysis amplifying <italic>mpc1</italic> WT (322 bp) or morphant band (189 bp). Un-injected embryos (UI) served as a second control group. (<bold>B</bold>) Observed penetrance for <italic>mpc1</italic> morpholino. (<bold>C</bold>) Observed phenotype for <italic>MPC1</italic> mRNA overexpression in WT embryos. (<bold>D</bold>) Rescue of pectoral fins (pfb) and underdeveloped midbrain (mb) in 72 hpf <italic>mpc1</italic> mo co-injected with human <italic>MPC1</italic> RNA (<italic>mpc1</italic> mo + <italic>MPC1</italic> RNA) was determined by in situ hybridization for <italic>id1</italic> and <italic>otx2</italic>, respectively. (<bold>E</bold>) Quantification of embryos with normal midbrain and eye development as measured by <italic>otx2</italic> staining. Statistical significance was analyzed using Fisher’s exact test. (<bold>F</bold>) PCR analysis confirming presence of human <italic>MPC1</italic> transcript (300 bp) in 48 hpf embryos.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.22706.007">http://dx.doi.org/10.7554/eLife.22706.007</ext-link></p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-22706-fig2-figsupp1-v1"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.22706.008</object-id><label>Figure 2—figure supplement 2.</label><caption><title><italic>mpc2</italic> morphants phenocopy loss of <italic>mpc1</italic>.</title><p>(<bold>A</bold>) Knockdown of <italic>mpc2</italic> expression in WT embryos (<italic>mpc2</italic> mo) resulted in phenotypes previously described for <italic>mpc1</italic> morphants including enlarged hindbrain (black arrows), body deformities and absence of pectoral fins (blue arrows). (<bold>B</bold>) PCR analysis using primers specific for amplifying <italic>mpc2</italic> WT (137 bp) or morphant band (1675 bp) confirmed knockdown of <italic>mpc2</italic> expression in 48 hpf embryos. (<bold>C</bold>) Observed penetrance for <italic>mpc2</italic> morpholino.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.22706.008">http://dx.doi.org/10.7554/eLife.22706.008</ext-link></p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-22706-fig2-figsupp2-v1"/></fig></fig-group></p><p>In situ hybridization with <italic>gata6</italic> revealed that the primordial gut formed (93%, n = 55) in <italic>mpc1</italic> mo but developed abnormally, as shown by reduced staining for <italic>fabp2</italic> (100%, n = 36), which marks the differentiated gut (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). Histological analyses on <italic>mpc1</italic> mo gut confirmed these findings, there were fewer cells comprising the gut tube and they appeared cuboidal and non-polarized (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). Additionally, intestinal folds were visibly lacking in the <italic>mpc1</italic> mo gut (black arrow, <xref ref-type="fig" rid="fig2">Figure 2C</xref>). In contrast, cross-section of the gut from control mo showed polarized columnar intestinal cells, with the nuclei lined up clearly against the basal membrane (<xref ref-type="fig" rid="fig2">Figure 2C</xref>).</p><p>Since APC has also been reported to play a crucial role in congenital hypertrophy of retinal pigment epithelium (CHRPE) in humans and normal ocular development in the zebrafish embryo, we examined the eyes of <italic>mpc1</italic> mo and found that <italic>irbp</italic>, a marker for photoreceptor and retinal pigmented epithelial cells, was severely reduced in <italic>mpc1</italic> mo (95%, n = 40) (<xref ref-type="fig" rid="fig2">Figure 2B</xref>) (<xref ref-type="bibr" rid="bib31">Nadauld et al., 2006b</xref>; <xref ref-type="bibr" rid="bib8">Chapman et al., 1989</xref>). Cross-section of <italic>mpc1</italic> mo eye revealed small lens and disorganized cell layers (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). The retinal cells appeared to be undifferentiated as supported by the loss of <italic>irbp</italic> expression (red arrow, <xref ref-type="fig" rid="fig2">Figure 2C</xref>).</p><p>Further phenotypic analyses of <italic>mpc1</italic> mo by in situ hybridization using tissue-specific markers exposed diminished maturation for brain (95%, n = 22) and fin buds (100%, n = 28) as indicated by <italic>ascl1a</italic> and <italic>id1</italic> expression, respectively (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). Also, <italic>mpc1</italic> mo hearts failed to loop as determined by <italic>myl7</italic> staining (100%, n = 39) (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). As with the gut, terminal differentiation of the pancreas in <italic>mpc1</italic> mo was severely reduced as assessed by <italic>trypsin</italic> expression, a marker for exocrine pancreas (100%, n = 28) (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). <italic>Insulin</italic>, denoting the endocrine pancreas, remained normal (100%, n = 25) (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). Cartilage staining with alcian blue confirmed the absence of pectoral fins and revealed improper jaw formation in <italic>mpc1</italic> mo (100%, n = 152) (<xref ref-type="fig" rid="fig2">Figure 2B</xref>).</p><p>We verified that the morphological defects we observed in <italic>mpc1</italic> mo were specifically due to knock down of <italic>mpc1</italic> by co-injecting with 0.5 ng of full length human <italic>MPC1</italic> mRNA and analyzing the embryos by in situ hybridization for <italic>id1</italic> and <italic>otx2</italic>, a marker for both the midbrain and eyes. Overexpression of <italic>MPC1</italic> mRNA alone resulted mostly in normal-appearing embryos, a small percentage exhibited cyclopia, severe body curvature and truncated tail (29%, n = 187) (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C</xref>). However, in co-injected embryos (<italic>mpc1</italic> mo + <italic>MPC1</italic> RNA), we found that <italic>MPC1</italic> mRNA restored fin development as indicated by <italic>id1</italic> staining (50%, n = 49) (<xref ref-type="fig" rid="fig2">Figure 2D</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1D</xref>). We obtained similar results with <italic>otx2</italic>, <italic>MPC1</italic> mRNA was able to rescue normal midbrain and eye development in <italic>mpc1</italic> mo (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1D and E</xref>). The presence of <italic>MPC1</italic> transcript was confirmed by PCR (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1F</xref>).</p><p><italic>mpc1</italic> and <italic>mpc2</italic> form a heterodimer complex that is responsible for transporting pyruvate from the inner mitochondrial space into the inner mitochondrial matrix (<xref ref-type="bibr" rid="bib5">Bricker et al., 2012</xref>; <xref ref-type="bibr" rid="bib19">Herzig et al., 2012</xref>). To examine whether loss of <italic>mpc2</italic> would result in similar phenotypes as <italic>mpc1</italic> mo, we knocked down its expression in WT embryos using antisense morpholino (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2A and B</xref>). We found that <italic>mpc2</italic> mo exhibited similar developmental defects as <italic>mpc1</italic> mo, such as smaller head and eyes, enlarged hindbrain vesicle (black arrows), body curvature, and absence of pectoral fins (blue arrows) (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2B</xref>). In contrast to <italic>mpc1</italic> mo, only a third of <italic>mpc2</italic> mo-injected embryos appeared morphant, the majority of which exhibited a mild phenotype (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2C</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>, data not shown). MPC2 expression is inconsistently altered in cancer and variably correlated with survival (<xref ref-type="bibr" rid="bib37">Schell et al., 2014</xref>). We therefore focused further studies on <italic>mpc1</italic>.</p></sec><sec id="s2-3"><title><italic>MPC1</italic> rescues intestinal differentiation in <italic>apc</italic>-deficient embryos</title><p>In light of our data relating reduced <italic>mpc1</italic> levels to failed intestinal differentiation, we sought to determine if re-expression of <italic>MPC1</italic> would rescue intestinal defects in <italic>apc</italic>-deficient zebrafish embryos. We injected 0.75 mM <italic>apc</italic> mo with or without 0.1 ng <italic>MPC1</italic> mRNA into WT embryos and evaluated intestinal differentiation by in situ hybridization for <italic>fabp2</italic>. Compared to <italic>apc</italic> mo (6%, n = 265), there was a significant increase in embryos with differentiated gut in the morpholino plus mRNA group (29%, n = 312) (<xref ref-type="fig" rid="fig3">Figure 3A,C</xref>). Control embryos all displayed normal <italic>fabp2</italic> expression (data not shown).<fig id="fig3" position="float"><object-id pub-id-type="doi">10.7554/eLife.22706.009</object-id><label>Figure 3.</label><caption><title><italic>MPC1</italic> rescues gut phenotype of <italic>apc mo</italic> and <italic>apc<sup>mcr</sup></italic>.</title><p>(<bold>A</bold>,<bold>B</bold>) In situ hybridization for <italic>fabp2</italic>, in 72 hpf WT embryos injected with cont mo, <italic>apc</italic> mo or both <italic>apc</italic> mo and human <italic>MPC1</italic> RNA (<italic>apc</italic> mo + <italic>MPC1</italic> RNA) (<bold>A</bold>). In situ hybridization for <italic>fabp2</italic> in 72 hpf <italic>apc</italic> WT, <italic>apc<sup>mcr</sup></italic> or <italic>apc<sup>mcr</sup></italic> injected with human <italic>MPC1</italic> mRNA (<italic>apc<sup>mcr</sup></italic> + <italic>MPC1</italic> RNA) (<bold>B</bold>). (<bold>C</bold>,<bold>D</bold>) Quantification of injected embryos with differentiated gut as determined by <italic>fabp2</italic> staining. Statistical significance was analyzed using Fisher’s exact test.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.22706.009">http://dx.doi.org/10.7554/eLife.22706.009</ext-link></p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-22706-fig3-v1"/></fig></p><p>We confirmed this finding by injecting 0.5 ng <italic>MPC1</italic> mRNA into <italic>apc<sup>mcr</sup></italic> and observed similar results, 40% of injected embryos re-expressed <italic>fabp2</italic> (n = 52) (<xref ref-type="fig" rid="fig3">Figure 3B,D</xref>). However, only 3% of un-injected <italic>apc<sup>mcr</sup></italic> showed <italic>fabp2</italic> staining (n = 29), while WT/het siblings were all positive (n = 80, data not shown). <italic>MPC1</italic> was also able to rescue cardiac defects in <italic>apc<sup>mcr</sup></italic>, as we saw improved blood circulation in injected mutants as well (data not shown). These results suggest that re-introduction of <italic>mpc1</italic> can drive intestinal differentiation.</p></sec><sec id="s2-4"><title>Knock down of <italic>mpc1</italic> or <italic>apc</italic> alters mitochondrial function</title><p>Because of the integral role of MPC1 in pyruvate metabolism, we next investigated if <italic>mpc1</italic> mo harbor metabolic defects as a consequence of diminished <italic>mpc1</italic> function. We assessed mitochondrial respiration by measuring oxidative consumption rates (OCR) in 72 hpf embryos and there was a significant reduction in OCR in <italic>mpc1</italic> mo compared to control (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). We also looked at triglyceride (TG) levels as an indicator of disturbance in normal energy utilization and observed a similar trend (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). Moreover, there was an extensive dysregulation of pyruvate metabolism upon loss of <italic>mpc1</italic>, as we discovered a profound upregulation of pyruvate metabolic genes in <italic>mpc1</italic> mo, suggesting a compensatory mechanism to account for reduced pyruvate transport across the inner mitochondrial membrane (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A and B</xref>). Knock down of <italic>mpc2</italic> did not affect <italic>mpc1</italic> transcript level (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1C</xref>).<fig-group><fig id="fig4" position="float"><object-id pub-id-type="doi">10.7554/eLife.22706.010</object-id><label>Figure 4.</label><caption><title>Knock down of <italic>mpc1</italic> or <italic>apc</italic> leads to altered mitochondrial respiration and pyruvate metabolism.</title><p>(<bold>A</bold>) Mitochondrial respiration was evaluated by measuring oxygen consumption rates (OCR) in 72 hpf embryos. (<bold>B</bold>) Triglyceride (TG) levels were determined in lysates prepared from 72 hpf embryos using a colorimetric assay. (<bold>C</bold>,<bold>D</bold>) Quantitative RT-PCR analysis of enzymes involved in pyruvate metabolism in <italic>apc</italic> mo and (<bold>C</bold>) <italic>apc<sup>mcr</sup></italic> (<bold>D</bold>) embryos. <italic>pyruvate dehydrogenase alpha 1a (pdha1a); pyruvate dehydrogenase kinase, isozyme 1 (pdk1); pyruvate kinase, muscle, a (pkma); citrate synthase (cs)</italic>. (<bold>E</bold>) Lactate levels in <italic>apc</italic> wild type (WT), un-injected <italic>apc<sup>mcr</sup></italic> (UI) or <italic>apc<sup>mcr</sup></italic> embryos injected with human <italic>MPC1</italic> mRNA (MPC1 RNA). For figures <bold>A–E</bold>, values represent mean ± SD. Graph shown above is representative of at least three independent experiments. Statistical significance was analyzed using unpaired t-test. (<bold>F</bold>,<bold>G</bold>,<bold>H</bold>) Gross phenotype (<bold>F</bold>), alcian blue staining (<bold>G</bold>) and in situ hybridization for <italic>fabp2</italic> (<bold>H</bold>) in <italic>pdha1a</italic>, <italic>pcxb</italic>, and <italic>pcxb</italic> + <italic>pdha1a</italic> mo. <italic>pcxb (pyruvate carboxylase b).</italic> See also <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplements 1</xref>, <xref ref-type="fig" rid="fig4s2">2</xref>.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.22706.010">http://dx.doi.org/10.7554/eLife.22706.010</ext-link></p><p> <supplementary-material id="SD2-data"><object-id pub-id-type="doi">10.7554/eLife.22706.011</object-id><label>Figure 4—source data 1.</label><caption><title>Mean and standard deviation values for <xref ref-type="fig" rid="fig4">Figure 4A,B,E</xref>; fold change calculations for <xref ref-type="fig" rid="fig4">Figure 4C,D</xref>.</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.22706.011">http://dx.doi.org/10.7554/eLife.22706.011</ext-link></p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-22706-fig4-data1-v1.xlsx"/></supplementary-material> </p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-22706-fig4-v1"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.22706.012</object-id><label>Figure 4—figure supplement 1.</label><caption><title>Knockdown of <italic>mpc1</italic> leads to dysregulated pyruvate metabolism.</title><p>(<bold>A</bold>) A simplified scheme showing key enzymes (in blue) involved in pyruvate transport and metabolism (adapted from <xref ref-type="bibr" rid="bib36">Schell and Rutter [2013]</xref>). (<bold>B</bold>) Quantitative RT-PCR analysis of pyruvate metabolism enzymes in <italic>mpc1</italic> mo. (<bold>C</bold>) Quantitative RT-PCR analysis of <italic>mpc1</italic> in <italic>mpc2</italic> mo. For <bold>B–C</bold>, values represent mean ± SD. Graph shown above is representative of at least three independent experiments. Statistical significance was analyzed using unpaired t-test. <italic>pyruvate dehydrogenase alpha 1a (pdha1a); pyruvate carboxylase b (pcxb); lactate dehydrogenase A4 (ldha); pyruvate dehydrogenase kinase, isozyme 1 (pdk1); citrate synthase (cs); solute carrier family 16, member 1 (slc16a1); solute carrier family 16, member 3 (slc16a3); pyruvate kinase, muscle, a (pkma); mitochondrial pyruvate carrier 2 (mpc2)</italic>.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.22706.012">http://dx.doi.org/10.7554/eLife.22706.012</ext-link></p><p> <supplementary-material id="SD3-data"><object-id pub-id-type="doi">10.7554/eLife.22706.013</object-id><label>Figure 4—figure supplement 1—source data 1.</label><caption><title>Fold change calculations for <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B,C</xref>.</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.22706.013">http://dx.doi.org/10.7554/eLife.22706.013</ext-link></p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-22706-fig4-figsupp1-data1-v1.xlsx"/></supplementary-material> </p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-22706-fig4-figsupp1-v1"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.22706.014</object-id><label>Figure 4—figure supplement 2.</label><caption><title>PCR analysis confirming knockdown of <italic>pdha1a, pcxb</italic>.</title><p>(<bold>A</bold>,<bold>B</bold>) cDNA from 48 hpf embryos injected with cont mo, <italic>pcxb</italic> mo or <italic>pdha1a</italic> mo was used to amplify a band corresponding to <italic>pcxb</italic> WT (355 bp) (<bold>A</bold>) or <italic>pdha1a</italic> WT (254 bp) (<bold>B</bold>). A negative control with no reverse transcriptase (-) was also included. Amplification of 18s served as control for input cDNA (67 bp). (<bold>C</bold>) Microinjection of WT embryos with <italic>pdha1a</italic> morpholino (<italic>pdha1a</italic> mo) resulted in a higher penetrance compared to <italic>pcxb</italic> morpholino (<italic>pcxb</italic> mo). Co-injection of both morpholinos gave the highest percentage of embryos with phenotype (<italic>pcxb</italic> mo + <italic>pdha1a</italic> mo).</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.22706.014">http://dx.doi.org/10.7554/eLife.22706.014</ext-link></p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-22706-fig4-figsupp2-v1"/></fig></fig-group></p><p>Earlier studies have reported that <italic>MPC1</italic> is downregulated in colon cancer and its expression positively correlates with <italic>APC</italic> (<xref ref-type="bibr" rid="bib37">Schell et al., 2014</xref>). Together with our previous data showing that <italic>mpc1</italic> is downregulated in <italic>apc</italic>-deficient zebrafish and that <italic>mpc1</italic> mo exhibit impaired oxidative respiration, we hypothesized that <italic>apc</italic> regulates <italic>mpc1</italic> and therefore, pyruvate metabolism overall. To test this, we evaluated mitochondrial respiration and TG levels in <italic>apc<sup>mcr </sup></italic>and <italic>apc</italic> mo and compared to appropriate controls, we observed significant defects in mitochondrial function upon loss of <italic>apc</italic> (<xref ref-type="fig" rid="fig4">Figure 4A,B</xref>). Several enzymes in the pyruvate pathway were also differentially regulated in <italic>apc<sup>mcr</sup></italic> or <italic>apc</italic> mo (<xref ref-type="fig" rid="fig4">Figure 4C,D</xref>).</p><p>To further validate that impaired mitochondrial function in <italic>apc<sup>mcr </sup></italic>is facilitated by reduced <italic>mpc1</italic> expression, we injected <italic>MPC1</italic> mRNA into <italic>apc</italic> mutant embryos and looked at lactate levels as indicator of improved mitochondrial function. Compared to un-injected <italic>apc<sup>mcr</sup></italic>, mutant embryos overexpressing <italic>MPC1</italic> showed a significant reduction in lactate (<xref ref-type="fig" rid="fig4">Figure 4E</xref>). <italic>apc</italic> WT/het sibs (WT) represent basal lactate levels in normal embryos (<xref ref-type="fig" rid="fig4">Figure 4E</xref>).</p><p>Pyruvate, after passing through the inner mitochondrial membrane, is converted to oxaloacetate and acetyl-CoA by pyruvate carboxylase (PC) and pyruvate dehydrogenase (PDH), respectively. To ascertain if the knock down of enzymes downstream of <italic>mpc1</italic> would result in a phenotype similar to <italic>mpc1</italic> mo, we targeted <italic>pcxb</italic> and <italic>pdha1a</italic>, separately and in tandem, with antisense morpholinos (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2A and B</xref>). Loss of either metabolic gene or both, resulted in morphant embryos that lacked pectoral fins (blue arrows), jaw (red arrows) and appeared identical to <italic>mpc1</italic> mo (<xref ref-type="fig" rid="fig4">Figures 4F–H</xref>, <xref ref-type="fig" rid="fig2">2A</xref>). Interestingly, knock down of <italic>pcxb</italic> resulted in only 22% of embryos with phenotype (n = 27) while targeting <italic>pdha1a</italic> gave a higher percentage of morphant embryos (63%, n = 19) (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2C</xref>). A synergistic effect was observed when both enzymes were diminished (83%, n = 18) (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2C</xref>). <italic>fabp2</italic> in situ staining (black arrows) also revealed intestinal developmental defects in the <italic>pdha1a</italic> mo<italic>, pcxb</italic> mo and <italic>pdha1a + pcxb</italic> morphant embryos (<xref ref-type="fig" rid="fig4">Figure 4H</xref>). Knock down of <italic>pcxb</italic> expression, however, not only resulted in low penetrance but mild phenotype as well (<xref ref-type="fig" rid="fig4">Figure 4F–H</xref>). This could be due to the activation of an alternative pathway where oxaloacetate can be derived from glutamine instead of pyruvate (<xref ref-type="bibr" rid="bib10">DeBerardinis et al., 2007</xref>).</p></sec><sec id="s2-5"><title>Decreased RA levels lead to aberrant pyruvate metabolism</title><p>To further elucidate how <italic>apc</italic> is controlling <italic>mpc1</italic>, we initially looked at Wnt signaling as one of the major roles of APC is to regulate degradation of β-catenin (<xref ref-type="bibr" rid="bib14">Fearnhead et al., 2001</xref>). Perturbation of the Wnt pathway by treatment of <italic>apc</italic> mo with 10 uM NS-398, a COX-2-specific inhibitor that has been shown to impair β-catenin activity in an <italic>apc</italic>-deficient background, did not affect <italic>mpc1</italic> or <italic>mpc2</italic> levels (<xref ref-type="fig" rid="fig5">Figure 5A</xref>) (<xref ref-type="bibr" rid="bib13">Eisinger et al., 2007</xref>). We did see a dramatic reduction in expression of known β-catenin target gene, <italic>mmp9</italic>, implying that <italic>apc</italic> regulation of <italic>mpc1</italic> is independent of Wnt (<xref ref-type="fig" rid="fig5">Figure 5A</xref>).<fig id="fig5" position="float"><object-id pub-id-type="doi">10.7554/eLife.22706.015</object-id><label>Figure 5.</label><caption><title>RA deficiency results in dysregulated pyruvate metabolism that is independent of Wnt pathway.</title><p>(<bold>A</bold>) <italic>apc</italic> mo treated either with DMSO control or 10 uM NS-398 were analyzed by qRT-PCR to determine expression levels of <italic>mpc1</italic>, <italic>mpc2</italic> and <italic>mmp9</italic>. (<bold>B</bold>,<bold>C</bold>) WT embryos treated with either DMSO control or 5 uM DEAB were analyzed by qRT-PCR to determine expression levels of enzymes involved in pyruvate metabolism. (<bold>D</bold>) Lactate levels in 72 hpf WT embryos treated with either DMSO or 5 uM DEAB. For figures <bold>A–D</bold>, values represent mean ± SD. Graph shown above is representative of 3 independent experiments. Statistical significance was analyzed using unpaired t-test. <italic>matrix metallopeptidase 9 (mmp9); solute carrier family 16, member 1 (slc16a1).</italic>.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.22706.015">http://dx.doi.org/10.7554/eLife.22706.015</ext-link></p><p> <supplementary-material id="SD4-data"><object-id pub-id-type="doi">10.7554/eLife.22706.016</object-id><label>Figure 5—source data 1.</label><caption><title>Fold change calculations for <xref ref-type="fig" rid="fig5">Figure 5A,B,C</xref>; mean and standard deviation values for <xref ref-type="fig" rid="fig5">Figure 5D</xref>.</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.22706.016">http://dx.doi.org/10.7554/eLife.22706.016</ext-link></p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-22706-fig5-data1-v1.xlsx"/></supplementary-material> </p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-22706-fig5-v1"/></fig></p><p>In addition to regulating Wnt signaling, <italic>apc</italic> controls the program of intestinal differentiation through regulation of RA levels, as we have previously shown (<xref ref-type="bibr" rid="bib21">Jette et al., 2004</xref>; <xref ref-type="bibr" rid="bib30">Nadauld et al., 2006a</xref>, <xref ref-type="bibr" rid="bib28">2004</xref>, <xref ref-type="bibr" rid="bib29">2005</xref>; <xref ref-type="bibr" rid="bib33">Rai et al., 2010</xref>; <xref ref-type="bibr" rid="bib40">Shelton et al., 2006</xref>). To interrogate the involvement of RA in pyruvate metabolism downstream of <italic>apc</italic>, we treated WT embryos with DMSO or 5 uM DEAB, a known inhibitor of RALDH which catalyzes the second step in the conversion of Vitamin A to the active metabolite, RA (<xref ref-type="bibr" rid="bib24">Marill et al., 2003</xref>; <xref ref-type="bibr" rid="bib35">Russo et al., 1988</xref>). By qRT-PCR, we found that <italic>mpc1</italic> and <italic>mpc2</italic> transcript levels went down significantly with inhibition of RA (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). Expanding our analyses to include other components of pyruvate metabolism, there were five other genes that were either up- or downregulated upon DEAB treatment, supporting the notion that the pyruvate metabolic program is altered at various points when RA levels are perturbed (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). The DEAB-treated embryos also had low lactate levels, further establishing that RA inhibition results in mitochondrial dysfunction (<xref ref-type="fig" rid="fig5">Figure 5D</xref>).</p></sec><sec id="s2-6"><title>Pyruvate metabolism is dysregulated in colon cancer</title><p>To further understand the implication of our findings in zebrafish, we employed publicly available curated databases to investigate mutations and gene expression alterations of pyruvate metabolism genes in human cancers. Using samples deposited at The Cancer Genome Atlas (TCGA), we selected for colon adenocarcinomas with mutations upstream of codon 1600 of APC, a region encompassing the MCR, and resulting in a truncated protein similar to those found in a majority of patients with FAP (<xref ref-type="bibr" rid="bib14">Fearnhead et al., 2001</xref>). Consistent with our previous data, we found that <italic>mpc1</italic> expression is significantly downregulated in colon adenocarcinomas with APC deletions (n = 91) compared to normal colon (n = 19) (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). We also looked at other genes involved in pyruvate transport and metabolism and interestingly, MPC1, MPC2, PDHA1 and PC showed consistent downregulation in a specific subset of colon adenocarcinomas known as colon mucinous adenocarcinomas (AC) (n = 22) (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A</xref>). In addition to altered gene expression, we also found colorectal cancer samples in COSMIC that had mutations both in APC and pyruvate metabolism enzymes. There were five samples with somatic APC deletions that had mutations in multiple pyruvate metabolism enzymes as well, most of which are predicted to be probably (**) or possibly (*) damaging, further supporting a genetic link between APC mutation and dysregulation of pyruvate metabolism (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1B</xref>).<fig-group><fig id="fig6" position="float"><object-id pub-id-type="doi">10.7554/eLife.22706.017</object-id><label>Figure 6.</label><caption><title>In silico analyses of <italic>APC</italic> and pyruvate metabolism gene alterations in cancer.</title><p>(<bold>A</bold>) <italic>MPC1</italic> expression levels in TCGA normal colon and colon adenocarcinoma samples harboring truncating mutations in APC upstream of codon 1600. Statistical significance was analyzed using Mann Whitney test. (<bold>B</bold>) ONCOMINE database was analyzed for gene expression alterations in pyruvate metabolism genes in all cancer types. A control group composed of Uniprot random genes was used for comparison. Graph shows percentage of up- and downregulated genes with respect to the total unique analyses for each gene tested for all cancer groups. Statistical significance was analyzed using Mann Whitney test. (<bold>C</bold>) cBioportal analysis to estimate Kaplan-Meier overall survival of TCGA colorectal adenocarcinoma and kidney chromophobe patients with or without alterations in pyruvate metabolism (PM) genes. For <bold>B–C</bold>, pyruvate metabolism genes used in meta-analyses: <italic>MPC1, MPC2, CS, PDK1, PDHA1, PC, PKLR, LDHA, SLC16A1, GYS1</italic>. See also <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>, <xref ref-type="supplementary-material" rid="SD5-data">Supplementary files 1</xref>, <xref ref-type="supplementary-material" rid="SD6-data">2</xref>.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.22706.017">http://dx.doi.org/10.7554/eLife.22706.017</ext-link></p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-22706-fig6-v1"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.22706.018</object-id><label>Figure 6—figure supplement 1.</label><caption><title>Pyruvate metabolism genes are mutated in human colon carcinomas.</title><p>(<bold>A</bold>) Gene expression levels of pyruvate metabolism genes in TCGA normal colon and colon mucinous adenocarcinoma (MA). Statistical significance was analyzed using Mann Whitney test. (<bold>B</bold>) Colon carcinomas harboring APC mutations were identified from the COSMIC database. Of the 35 samples that were found, five had multiple mutations in pyruvate metabolism genes that are predicted to be at least possibly damaging based on Polyphen2 in silico protein analysis. (***) – deletion; Polyphen2 prediction: (**) – probably damaging, (*) – possibly damaging, (<italic>italics</italic>) – benign.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.22706.018">http://dx.doi.org/10.7554/eLife.22706.018</ext-link></p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-22706-fig6-figsupp1-v1"/></fig></fig-group></p><p>Several studies have shown that individual genes in the pyruvate metabolism pathway are altered in various cancer types (<xref ref-type="bibr" rid="bib17">Gray et al., 2014</xref>; <xref ref-type="bibr" rid="bib37">Schell et al., 2014</xref>). Using Oncomine, we extended these studies by treating the genes involved in pyruvate transport and metabolism as a group (n = 10). We discovered that this pathway is significantly dysregulated in cancer compared to a group of randomly-generated Uniprot genes (n = 55) (<xref ref-type="fig" rid="fig6">Figure 6B</xref>, <xref ref-type="supplementary-material" rid="SD5-data">Supplementary file 1</xref>). We then looked at overall survival for patients, with or without mutations and/or gene expression changes in the pyruvate metabolism gene set using TCGA samples in cBioportal. Out of 21 cancer types that we analyzed, only colorectal adenocarcinoma and kidney chromophobe carcinoma showed a significant difference in overall survival between the two groups (<xref ref-type="fig" rid="fig6">Figure 6C</xref>, <xref ref-type="supplementary-material" rid="SD6-data">Supplementary file 2</xref>).</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Recent identification of <italic>MPC1</italic> and <italic>MPC2</italic>, genes responsible for pyruvate uptake into the mitochondrial matrix, has added a new complexity to targeting pyruvate metabolism in human disorders, including cancer (<xref ref-type="bibr" rid="bib17">Gray et al., 2014</xref>; <xref ref-type="bibr" rid="bib5">Bricker et al., 2012</xref>; <xref ref-type="bibr" rid="bib19">Herzig et al., 2012</xref>). How dysregulation of metabolism relates to the accumulation of genetic hits that cause tumor suppression has largely been unstudied. Here, we demonstrate a direct relationship between loss of a key tumor suppressor gene, <italic>APC</italic>, and dysregulation of <italic>MPC1</italic>. Our finding that <italic>mpc1</italic> expression is downregulated in embryos harboring a genetic mutation (<italic>apc<sup>mcr</sup></italic>) or knocked down expression (<italic>apc mo</italic>) of <italic>apc</italic> is reflected in human tumors as well, where we not only discovered a significant downregulation of <italic>MPC1</italic> expression in colon adenocarcinomas with APC deletions, but also samples possessing mutations in both APC and several pyruvate metabolism enzymes (<xref ref-type="fig" rid="fig1">Figure 1</xref>, <xref ref-type="fig" rid="fig6">Figure 6</xref>, <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>). Our meta-analyses of human cancer data sets also revealed extensive dysregulation of pyruvate metabolism, at multiple points in the pathway, and this incidence of altered gene expression of pyruvate metabolism genes in cancer is significantly more prevalent compared to a group of randomly selected genes (<xref ref-type="fig" rid="fig6">Figure 6</xref>, <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>, <xref ref-type="supplementary-material" rid="SD5-data">Supplementary file 1</xref>). It is remarkable how <italic>MPC1</italic> and <italic>MPC2</italic>, <italic>PDHA1</italic> and <italic>PC</italic>—genes that are involved in the transport and conversion of pyruvate in the inner mitochondrial matrix, respectively—are all significantly downregulated in a subset of colon adenocarcinomas categorized as colon mucinous adenocarcinomas, as loss of these genes essentially shuts down oxidative phosphorylation in the mitochondria (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>). Interestingly, additional in silico analyses suggest a potential use of pyruvate metabolism genes as prognostic markers for colorectal adenocarcinoma and kidney chromophobe carcinoma, as we found a strong correlation between aberrations in pyruvate metabolism genes with poor overall survival in these cancer types (<xref ref-type="fig" rid="fig6">Figure 6</xref>).</p><p>It is interesting to note that there are differences in the dysregulation of pyruvate metabolism genes in <italic>apc<sup>mcr</sup></italic>/<italic>apc mo</italic> and <italic>mpc1 mo</italic> (<xref ref-type="fig" rid="fig4">Figure 4</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>). APC is a multifunctional protein that has critical roles in various cellular processes (<xref ref-type="bibr" rid="bib15">Fodde, 2003</xref>). In addition, regulation of other metabolic genes by APC could occur in parallel with regulation of <italic>mpc1. mpc1</italic> knock down alone, therefore, would not alter the expression of these genes in the same way as knock down of <italic>apc</italic>. Confirming a functional epistatic relationship between <italic>apc</italic> and <italic>mpc1</italic>, knock down of <italic>mpc1</italic> in WT embryos resulted in phenotypes that have been previously reported for impaired <italic>apc</italic> function (<xref ref-type="fig" rid="fig2">Figure 2</xref>) (<xref ref-type="bibr" rid="bib28">Nadauld et al., 2004</xref>; <xref ref-type="bibr" rid="bib20">Hurlstone et al., 2003</xref>). APC has been shown to positively regulate glycogen synthase kinase-3 (GSK-3) activity, an enzyme that inhibits glycogen synthase (GS) which is involved in converting glucose into glycogen for storage (<xref ref-type="bibr" rid="bib3">Bouskila et al., 2010</xref>; <xref ref-type="bibr" rid="bib44">Valvezan et al., 2012</xref>). Taken together, these findings suggest a major role for APC in controlling cellular bioenergetics and homeostasis, as it can affect glycogen synthesis and oxidative phosphorylation through GSK-3 and MPC1, respectively.</p><p>The exact role of metabolism in cancer as a driver versus passenger process has been unclear. Indeed, roles for metabolism in directing cell fate and differentiation decisions are only now being considered (<xref ref-type="bibr" rid="bib37">Schell et al., 2014</xref>; <xref ref-type="bibr" rid="bib4">Bracha et al., 2010</xref>; <xref ref-type="bibr" rid="bib41">Sperber et al., 2015</xref>; <xref ref-type="bibr" rid="bib48">Yanes et al., 2010</xref>; <xref ref-type="bibr" rid="bib50">Zhou et al., 2012</xref>). The rescue of intestinal differentiation defects in embryos with impaired <italic>apc</italic> function by exogenous <italic>MPC1</italic> mRNA establishes a clear role for metabolic programming as a switch that can control cell fate decisions (<xref ref-type="fig" rid="fig3">Figure 3</xref>). Mechanistic insights into regulatory pathways that control metabolism and how perturbations in cellular bioenergetics effect cell differentiation and proliferation can lead to a better understanding of normal development and tumorigenesis. In this respect, the role of retinoic acid in promoting cell fate and differentiation remains undefined. Our studies suggest that RA may control a program of metabolism that is permissive for intestinal differentiation. The actions of RA are complex, and it is likely that the effects of RA on metabolism are indirect. Consistent with this, treatment of either WT or <italic>apc<sup>mcr</sup></italic> embryos with RA did not result in an immediate induction of <italic>mpc1</italic> (data not shown).</p><p>To conclude, we present a novel role for <italic>apc</italic> in controlling a metabolic program driving intestinal differentiation through regulation of <italic>mpc1</italic>. Our data strongly support the notion that metabolic changes are a major part of the decision process in determining cell fate and provide a better understanding of how cancer genetics is linked with biochemical metabolic pathways.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Zebrafish maintenance</title><p>Wild-type (WT) <italic>TU</italic> (RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/ZIRC_ZL57">ZIRC_ZL57</ext-link>) and <italic>apc<sup>WT/mcr</sup></italic> (RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/ZFIN_ZDB-ALT-050914-2">ZFIN_ZDB-ALT-050914-2</ext-link>) Danio <italic>rerio</italic> (zebrafish) were maintained as previously described (<xref ref-type="bibr" rid="bib47">Westerfield, 1995</xref>). Fertilized embryos were collected following natural spawnings in 1 × E3 medium (286 mg/L NaCl, 13 mg/L KCl, 48 mg/L CaCl<sub>2</sub>·2H<sub>2</sub>O, 40 mg/L MgSO<sub>4</sub>, 0.01% methylene blue) and allowed to develop at 28.5°C.</p></sec><sec id="s4-2"><title>Morpholino and RNA microinjections</title><p>Morpholino oligonucleotides were obtained from Gene Tools LLC (Philomath, OR) and solubilized to 1 mM or 3 mM stock solutions in 1x Danieau buffer. For microinjections, 1 nl of morpholino was injected into WT embryos at the 1- to 2-cell stages (<xref ref-type="bibr" rid="bib12">Draper et al., 2001</xref>). Knock down of gene expression was assessed by PCR. Primers were designed according to guidelines recommended by Gene Tools (<ext-link ext-link-type="uri" xlink:href="http://www.gene-tools.com">www.gene-tools.com</ext-link>) to amplify WT and splice-blocked morphant bands. <italic>z18s</italic> was amplified as a control gene.</p><p>For RNA rescue experiments, full length human RNA transcripts were transcribed from linearized DNA using mMESSAGE mMACHINE transcription kit (Ambion - Waltham, MA). For microinjections, 1–2 nl of RNA was injected into embryos at the 1- to 2-cell stages. Overexpression of mRNA transcript was assessed by PCR. Statistical analyses were performed using Fisher’s exact test (GraphPad Prism v 6.04, RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_002798">SCR_002798</ext-link>).</p><p>A complete list of morpholinos, PCR primers and working concentrations used are provided in <xref ref-type="supplementary-material" rid="SD7-data">Supplementary files 3</xref>–<xref ref-type="supplementary-material" rid="SD8-data">4</xref>.</p></sec><sec id="s4-3"><title>Zebrafish drug treatments</title><p>Wild type embryos were given DEAB (VWR International - Radnor, PA) at 5 µM. <italic>apc</italic> morphants were treated with 10 µM NS398 (Cayman Chemical - Ann Arbour, MI). Embryos were harvested at 72 hpf in RNAlater (Ambion) for RNA/cDNA prep.</p></sec><sec id="s4-4"><title>In situ hybridization</title><p>In situ hybridizations were performed as previously described using digoxigenin-labeled riboprobes for <italic>ascl1a (achaete-scute family bHLH transcription factor 1a)</italic>, <italic>fabp2 (fatty acid binding protein 2, intestinal)</italic>, <italic>gata6 (GATA binding protein 6)</italic>, <italic>id1 (inhibitor of DNA binding 1)</italic>, <italic>insulin</italic>, <italic>irbp (interphotoreceptor retinoid-binding protein)</italic>, <italic>mpc1 (mitochondrial pyruvate carrier 1)</italic>, <italic>mpc2 (mitochondrial pyruvate carrier 2)</italic>, <italic>myl7 (myosin, light chain 7, regulatory)</italic>, <italic>otx2 (orthodenticle homeobox 2)</italic> and <italic>trypsin</italic> (<xref ref-type="bibr" rid="bib43">Thisse and Thisse, 2008</xref>). Embryos were cleared in 2:1 benzyl benzoate/benzyl alcohol solution and documented using an Olympus SZX12/DP71 imaging system (Olympus Corporation - Japan). RNA Reference Sequences deposited in ZFIN (zfin.org, RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_002560">SCR_002560</ext-link>) were used in designing the riboprobes.</p></sec><sec id="s4-5"><title>Quantitative RT-PCR</title><p>RNA from zebrafish embryo lysates was isolated using the RNeasy kit (Qiagen - Germany). cDNA was synthesized from 1 µg of total RNA using iScript (Bio-Rad - Hercules, CA). Intron-spanning primers, when possible, were designed using the Universal ProbeLibrary Assay Design Center (Roche Applied Science). A complete list of primer sets is provided in <xref ref-type="supplementary-material" rid="SD9-data">Supplementary file 5</xref>.</p><p>PCR master mix was prepared with the FastStart Essential DNA Probe Master kit and Universal ProbeLibrary probes according to the manufacturer’s protocols (Roche Applied Science - Germany). PCR was performed in triplicate using the LightCycler 96 System (Roche Applied Science) with 45 cycles of amplification and annealing temperature of 60°C. Fold change in gene expression was measured by normalizing against 18S rRNA and comparing test group with control.</p></sec><sec id="s4-6"><title>Alcian blue assay</title><p>Cartilage of 96 hpf embryos was stained with alcian blue as previously described (<xref ref-type="bibr" rid="bib32">Neuhauss et al., 1996</xref>). Briefly, embryos were fixed in 4% sucrose-buffered paraformaldehyde, bleached with 30% hydrogen peroxide for 2 hr and stained with alcian blue overnight. The embryos were then cleared in acidic ethanol for 4 hr, dehydrated stepwise in ethanol and stored either in glycerol or 2:1 benzyl benzoate/benzyl alcohol solution. Stained embryos were examined using an Olympus SZX12/DP71 imaging system (Olympus Corporation).</p></sec><sec id="s4-7"><title>Seahorse bioscience XF assay</title><p>Metabolic respiration in 72 hpf embryos, expressed as oxygen consumption rate (OCR), was measured using XF24 Extracellular Flux Analyzer (Seahorse Bioscience - North Billerica, MA) as previously described (<xref ref-type="bibr" rid="bib42">Stackley et al., 2011</xref>). As a minor modification, mixing step was omitted during measurement cycle. Statistical analyses were performed using unpaired t-test (GraphPad Prism v 7.02, RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_002798">SCR_002798</ext-link>).</p></sec><sec id="s4-8"><title>Triglyceride (TG) assay</title><p>Embryos were harvested at 72 hpf and homogenized in 0.05% PBST +1X protease inhibitor. TG levels were determined using the Infinity Triglycerides Liquid Stable Reagent (Thermo Scientific - Waltham, MA) by measuring absorbance at 540 nm. Total protein concentration was determined using the DC Protein Assay (Bio-Rad) to normalize TG levels. Statistical analyses were performed using unpaired t-test (GraphPad Prism v 7.02, RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_002798">SCR_002798</ext-link>).</p></sec><sec id="s4-9"><title>Lactate assay</title><p>Lactate levels were measured in 72 hpf embryos using the EnzyChrom L-Lactate Assay kit (BioAssay Systems - Hayward, CA) as previously described (<xref ref-type="bibr" rid="bib2">Bestman et al., 2015</xref>). Groups of 25–50 embryos were used in the assay. Statistical analyses were performed using unpaired t-test (GraphPad Prism v 7.02, RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_002798">SCR_002798</ext-link>).</p></sec><sec id="s4-10"><title>Histological analyses</title><p>Embryos were fixed in 10% neutral buffered formalin, dehydrated in 70% ethanol and embedded in paraffin. Five-micron sections were cut using a Shandon Finesse E Microtome (Thermo Scientific) and stained with hematoxylin and eosin (H and E). Sections were analyzed using a Nikon Eclipse 80i/DS-Fi1 imaging system (Nikon Instruments Inc - Japan).</p></sec><sec id="s4-11"><title>Bioinformatic analyses</title><p>Publicly available curated databases and analysis software were utilized to examine mutations and gene expression alterations in APC and pyruvate metabolism enzymes (MPC1, MPC2, CS, PDK1, PDHA1, PC, PKLR, LDHA, SLC16A1,GYS1). COSMIC (<ext-link ext-link-type="uri" xlink:href="http://cancer.sanger.ac.uk/cosmic">http://cancer.sanger.ac.uk/cosmic</ext-link>, RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_002260">SCR_002260</ext-link>) was mined for mutations that are found in human cancers (<xref ref-type="bibr" rid="bib16">Forbes et al., 2015</xref>). Polyphen2 (<ext-link ext-link-type="uri" xlink:href="http://genetics.bwh.harvard.edu/pph2/index.shtml">http://genetics.bwh.harvard.edu/pph2/index.shtml</ext-link>, RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_008584">SCR_008584</ext-link>) was used to predict functional and structural consequences of amino acid substitutions in proteins mentioned above (<xref ref-type="bibr" rid="bib1">Adzhubei et al., 2010</xref>).</p><p>For <italic>MPC1</italic> expression analysis, Oncomine (<ext-link ext-link-type="uri" xlink:href="http://www.oncomine.org">www.oncomine.org</ext-link>, RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_010949">SCR_010949</ext-link>) was utilized to determine the colon adenocarcinoma subset (n = 101) in the TCGA (<ext-link ext-link-type="uri" xlink:href="http://cancergenome.nih.gov">http://cancergenome.nih.gov</ext-link>, RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_003193">SCR_003193</ext-link>) colorectal carcinoma sample set (n = 237), which was further selected, using COSMIC, for truncating mutations in APC upstream of codon 1600, encompassing the MCR region (n = 91). <italic>MPC1</italic> expression level in these samples was compared with normal colon (n = 19). Colon mucinous adenocarcinomas (n = 22) within the same TCGA colorectal carcinoma sample set were analyzed for gene expression of pyruvate metabolism genes, with normal colon as control. Statistical analysis was performed using Mann Whitney test (GraphPad Prism v 6.04, RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_002798">SCR_002798</ext-link>).</p><p>Oncomine also allowed for gene expression analysis of individual pyruvate metabolism genes (n = 10) and randomly selected Uniprot genes (n = 55) (<ext-link ext-link-type="uri" xlink:href="http://www.uniprot.org/uniprot/?query=reviewed:yes+AND+organism:9606&amp;random=yes">http://www.uniprot.org/uniprot/?query=reviewed:yes+AND+organism:9606&amp;random=yes</ext-link>, RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_002380">SCR_002380</ext-link>) in multiple cancer types employing these thresholds: <italic>p value</italic> = 0.001; <italic>fold-change</italic> = 1.5; <italic>gene rank</italic> = top 10%; <italic>data type</italic> = all. A plot was generated to show percentage of datasets meeting set thresholds with respect to total unique analyses for each gene tested in both groups. Statistical analysis was performed using unpaired t-test (GraphPad Prism v 6.04, RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_002798">SCR_002798</ext-link>).</p><p>Overall survival in 21 different TCGA cancer types, segregated by presence of mutations in pyruvate metabolism genes, was analyzed with cBioportal (<ext-link ext-link-type="uri" xlink:href="http://www.cbioportal.org/index.do">http://www.cbioportal.org/index.do</ext-link>, RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_014555">SCR_014555</ext-link>) (<xref ref-type="bibr" rid="bib6">Cerami et al., 2012</xref>). To verify the specificity of our pyruvate metabolism gene set as predictor of overall survival, four groups of ten random genes from Uniprot were utilized as a negative control gene set.</p></sec><sec id="s4-12"><title>Statistical analyses</title><p>Unpaired t-test was used to compare two unmatched, independent groups. Fisher’s exact test was used to determine if outcome is related to a categorical condition by more than chance. Mann-Whitney test was used to compare distribution of two unmatched groups. For fold change data, statistical significance was determined from t-test analyses of relative gene expression. For sample size calculations, the minimum number of samples per group (95% power) was determined by assuming the probability of the defect in the control group is 5% or lower and 80% in the experimental group.</p></sec></sec></body><back><ack id="ack"> <title>Acknowledgements</title> <p>We wish to thank the following: S Lee and HY Lim for assistance with the TG assay, A Vara for technical support, and OMRF Core Labs. This work was supported by NCI/NIH (RO1 CA116468NIH, [DAJ]), Samuel Waxman Cancer Research Foundation, Oklahoma Center for Adult Stem Cell Research (OCASCR) and Oklahoma Medical Research Foundation (OMRF).</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>ITS, Conceptualization, Formal analysis, Investigation, Visualization, Writing—original draft, Project administration, Writing—review and editing</p></fn><fn fn-type="con" id="con2"><p>RGCD, Formal analysis, Investigation, Visualization, Writing—original draft, Writing—review and editing</p></fn><fn fn-type="con" id="con3"><p>BNM, Investigation, Writing—review and editing</p></fn><fn fn-type="con" id="con4"><p>SH, Investigation</p></fn><fn fn-type="con" id="con5"><p>KAO, Resources</p></fn><fn fn-type="con" id="con6"><p>AEG, Formal analysis, Investigation, Writing—review and editing</p></fn><fn fn-type="con" id="con7"><p>KB, Formal analysis, Investigation, Writing—review and editing</p></fn><fn fn-type="con" id="con8"><p>CS, Investigation, Writing—review and editing</p></fn><fn fn-type="con" id="con9"><p>HVR, Resources</p></fn><fn fn-type="con" id="con10"><p>JR, Resources, Writing—review and editing</p></fn><fn fn-type="con" id="con11"><p>DAJ, Conceptualization, Supervision, Funding acquisition, Writing—original draft, Writing—review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to approved Institutional Animal Care And Use Committee (IACUC) protocol 14-08 of the Oklahoma Medical Research Foundation.</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="SD5-data"><object-id pub-id-type="doi">10.7554/eLife.22706.019</object-id><label>Supplementary file 1.</label><caption><title>Raw data for oncomine analyses of pyruvate metabolism and random gene dataset expression percent total dysregulation (plotted in <xref ref-type="fig" rid="fig6">Figure 6B</xref>).</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.22706.019">http://dx.doi.org/10.7554/eLife.22706.019</ext-link></p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-22706-supp1-v1.xlsx"/></supplementary-material><supplementary-material id="SD6-data"><object-id pub-id-type="doi">10.7554/eLife.22706.020</object-id><label>Supplementary file 2.</label><caption><title>Overall survival kaplan-meier estimate of pyruvate metabolism geneset alterations using cBioportal (sorted by lowest to highest LogRank Test P-Value).</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.22706.020">http://dx.doi.org/10.7554/eLife.22706.020</ext-link></p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-22706-supp2-v1.xlsx"/></supplementary-material><supplementary-material id="SD7-data"><object-id pub-id-type="doi">10.7554/eLife.22706.021</object-id><label>Supplementary file 3.</label><caption><title>List of morpholinos.</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.22706.021">http://dx.doi.org/10.7554/eLife.22706.021</ext-link></p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-22706-supp3-v1.xlsx"/></supplementary-material><supplementary-material id="SD8-data"><object-id pub-id-type="doi">10.7554/eLife.22706.022</object-id><label>Supplementary file 4.</label><caption><title>List of PCR primers.</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.22706.022">http://dx.doi.org/10.7554/eLife.22706.022</ext-link></p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-22706-supp4-v1.xlsx"/></supplementary-material><supplementary-material id="SD9-data"><object-id pub-id-type="doi">10.7554/eLife.22706.023</object-id><label>Supplementary file 5.</label><caption><title>List of qRT-PCR primers.</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.22706.023">http://dx.doi.org/10.7554/eLife.22706.023</ext-link></p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-22706-supp5-v1.xlsx"/></supplementary-material></sec><ref-list> <title>References</title> <ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adzhubei</surname><given-names>IA</given-names></name><name><surname>Schmidt</surname><given-names>S</given-names></name><name><surname>Peshkin</surname><given-names>L</given-names></name><name><surname>Ramensky</surname><given-names>VE</given-names></name><name><surname>Gerasimova</surname><given-names>A</given-names></name><name><surname>Bork</surname><given-names>P</given-names></name><name><surname>Kondrashov</surname><given-names>AS</given-names></name><name><surname>Sunyaev</surname><given-names>SR</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>A method and server for predicting damaging missense mutations</article-title><source>Nature Methods</source><volume>7</volume><fpage>248</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.1038/nmeth0410-248</pub-id><pub-id pub-id-type="pmid">20354512</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bestman</surname><given-names>JE</given-names></name><name><surname>Stackley</surname><given-names>KD</given-names></name><name><surname>Rahn</surname><given-names>JJ</given-names></name><name><surname>Williamson</surname><given-names>TJ</given-names></name><name><surname>Chan</surname><given-names>SS</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The cellular and molecular progression of mitochondrial dysfunction induced by 2,4-dinitrophenol in developing zebrafish embryos</article-title><source>Differentiation</source><volume>89</volume><fpage>51</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1016/j.diff.2015.01.001</pub-id><pub-id pub-id-type="pmid">25771346</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bouskila</surname><given-names>M</given-names></name><name><surname>Hunter</surname><given-names>RW</given-names></name><name><surname>Ibrahim</surname><given-names>AF</given-names></name><name><surname>Delattre</surname><given-names>L</given-names></name><name><surname>Peggie</surname><given-names>M</given-names></name><name><surname>van Diepen</surname><given-names>JA</given-names></name><name><surname>Voshol</surname><given-names>PJ</given-names></name><name><surname>Jensen</surname><given-names>J</given-names></name><name><surname>Sakamoto</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Allosteric regulation of glycogen synthase controls glycogen synthesis in muscle</article-title><source>Cell Metabolism</source><volume>12</volume><fpage>456</fpage><lpage>466</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2010.10.006</pub-id><pub-id pub-id-type="pmid">21035757</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bracha</surname><given-names>AL</given-names></name><name><surname>Ramanathan</surname><given-names>A</given-names></name><name><surname>Huang</surname><given-names>S</given-names></name><name><surname>Ingber</surname><given-names>DE</given-names></name><name><surname>Schreiber</surname><given-names>SL</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Carbon metabolism-mediated myogenic differentiation</article-title><source>Nature Chemical Biology</source><volume>6</volume><fpage>202</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1038/nchembio.301</pub-id><pub-id pub-id-type="pmid">20081855</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bricker</surname><given-names>DK</given-names></name><name><surname>Taylor</surname><given-names>EB</given-names></name><name><surname>Schell</surname><given-names>JC</given-names></name><name><surname>Orsak</surname><given-names>T</given-names></name><name><surname>Boutron</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>YC</given-names></name><name><surname>Cox</surname><given-names>JE</given-names></name><name><surname>Cardon</surname><given-names>CM</given-names></name><name><surname>Van Vranken</surname><given-names>JG</given-names></name><name><surname>Dephoure</surname><given-names>N</given-names></name><name><surname>Redin</surname><given-names>C</given-names></name><name><surname>Boudina</surname><given-names>S</given-names></name><name><surname>Gygi</surname><given-names>SP</given-names></name><name><surname>Brivet</surname><given-names>M</given-names></name><name><surname>Thummel</surname><given-names>CS</given-names></name><name><surname>Rutter</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>A mitochondrial pyruvate carrier required for pyruvate uptake in yeast, Drosophila, and humans</article-title><source>Science</source><volume>337</volume><fpage>96</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1126/science.1218099</pub-id><pub-id pub-id-type="pmid">22628558</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cerami</surname><given-names>E</given-names></name><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Dogrusoz</surname><given-names>U</given-names></name><name><surname>Gross</surname><given-names>BE</given-names></name><name><surname>Sumer</surname><given-names>SO</given-names></name><name><surname>Aksoy</surname><given-names>BA</given-names></name><name><surname>Jacobsen</surname><given-names>A</given-names></name><name><surname>Byrne</surname><given-names>CJ</given-names></name><name><surname>Heuer</surname><given-names>ML</given-names></name><name><surname>Larsson</surname><given-names>E</given-names></name><name><surname>Antipin</surname><given-names>Y</given-names></name><name><surname>Reva</surname><given-names>B</given-names></name><name><surname>Goldberg</surname><given-names>AP</given-names></name><name><surname>Sander</surname><given-names>C</given-names></name><name><surname>Schultz</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data</article-title><source>Cancer Discovery</source><volume>2</volume><fpage>401</fpage><lpage>404</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-12-0095</pub-id><pub-id pub-id-type="pmid">22588877</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cerwenka</surname><given-names>H</given-names></name><name><surname>Aigner</surname><given-names>R</given-names></name><name><surname>Bacher</surname><given-names>H</given-names></name><name><surname>Werkgartner</surname><given-names>G</given-names></name><name><surname>el-Shabrawi</surname><given-names>A</given-names></name><name><surname>Quehenberger</surname><given-names>F</given-names></name><name><surname>Mischinger</surname><given-names>HJ</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>TUM2-PK (pyruvate kinase type tumor M2), CA19-9 and CEA in patients with benign, malignant and metastasizing pancreatic lesions</article-title><source>Anticancer Research</source><volume>19</volume><fpage>849</fpage><lpage>851</lpage><pub-id pub-id-type="pmid">10216504</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chapman</surname><given-names>PD</given-names></name><name><surname>Church</surname><given-names>W</given-names></name><name><surname>Burn</surname><given-names>J</given-names></name><name><surname>Gunn</surname><given-names>A</given-names></name></person-group><year iso-8601-date="1989">1989</year><article-title>Congenital hypertrophy of retinal pigment epithelium: a sign of familial adenomatous polyposis</article-title><source>British Medical Journal</source><volume>298</volume><fpage>353</fpage><lpage>354</lpage><pub-id pub-id-type="doi">10.1136/bmj.298.6670.353</pub-id><pub-id pub-id-type="pmid">2538178</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Christofk</surname><given-names>HR</given-names></name><name><surname>Vander Heiden</surname><given-names>MG</given-names></name><name><surname>Harris</surname><given-names>MH</given-names></name><name><surname>Ramanathan</surname><given-names>A</given-names></name><name><surname>Gerszten</surname><given-names>RE</given-names></name><name><surname>Wei</surname><given-names>R</given-names></name><name><surname>Fleming</surname><given-names>MD</given-names></name><name><surname>Schreiber</surname><given-names>SL</given-names></name><name><surname>Cantley</surname><given-names>LC</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth</article-title><source>Nature</source><volume>452</volume><fpage>230</fpage><lpage>233</lpage><pub-id pub-id-type="doi">10.1038/nature06734</pub-id><pub-id pub-id-type="pmid">18337823</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeBerardinis</surname><given-names>RJ</given-names></name><name><surname>Mancuso</surname><given-names>A</given-names></name><name><surname>Daikhin</surname><given-names>E</given-names></name><name><surname>Nissim</surname><given-names>I</given-names></name><name><surname>Yudkoff</surname><given-names>M</given-names></name><name><surname>Wehrli</surname><given-names>S</given-names></name><name><surname>Thompson</surname><given-names>CB</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis</article-title><source>PNAS</source><volume>104</volume><fpage>19345</fpage><lpage>19350</lpage><pub-id pub-id-type="doi">10.1073/pnas.0709747104</pub-id><pub-id pub-id-type="pmid">18032601</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diaz-Ruiz</surname><given-names>R</given-names></name><name><surname>Rigoulet</surname><given-names>M</given-names></name><name><surname>Devin</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>The warburg and Crabtree effects: on the origin of cancer cell energy metabolism and of yeast glucose repression</article-title><source>Biochimica Et Biophysica Acta (BBA) - Bioenergetics</source><volume>1807</volume><fpage>568</fpage><lpage>576</lpage><pub-id pub-id-type="doi">10.1016/j.bbabio.2010.08.010</pub-id><pub-id pub-id-type="pmid">20804724</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Draper</surname><given-names>BW</given-names></name><name><surname>Morcos</surname><given-names>PA</given-names></name><name><surname>Kimmel</surname><given-names>CB</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Inhibition of zebrafish fgf8 pre-mRNA splicing with morpholino oligos: a quantifiable method for gene knockdown</article-title><source>Genesis</source><volume>30</volume><fpage>154</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.1002/gene.1053</pub-id><pub-id pub-id-type="pmid">11477696</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eisinger</surname><given-names>AL</given-names></name><name><surname>Nadauld</surname><given-names>LD</given-names></name><name><surname>Shelton</surname><given-names>DN</given-names></name><name><surname>Prescott</surname><given-names>SM</given-names></name><name><surname>Stafforini</surname><given-names>DM</given-names></name><name><surname>Jones</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Retinoic acid inhibits beta-catenin through suppression of Cox-2: a role for truncated adenomatous polyposis coli</article-title><source>Journal of Biological Chemistry</source><volume>282</volume><fpage>29394</fpage><lpage>29400</lpage><pub-id pub-id-type="doi">10.1074/jbc.M609768200</pub-id><pub-id pub-id-type="pmid">17673467</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fearnhead</surname><given-names>NS</given-names></name><name><surname>Britton</surname><given-names>MP</given-names></name><name><surname>Bodmer</surname><given-names>WF</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>The ABC of APC</article-title><source>Human Molecular Genetics</source><volume>10</volume><fpage>721</fpage><lpage>733</lpage><pub-id pub-id-type="doi">10.1093/hmg/10.7.721</pub-id><pub-id pub-id-type="pmid">11257105</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fodde</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>The multiple functions of tumour suppressors: it's all in APC</article-title><source>Nature Cell Biology</source><volume>5</volume><fpage>190</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.1038/ncb0303-190</pub-id><pub-id pub-id-type="pmid">12646874</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forbes</surname><given-names>SA</given-names></name><name><surname>Beare</surname><given-names>D</given-names></name><name><surname>Gunasekaran</surname><given-names>P</given-names></name><name><surname>Leung</surname><given-names>K</given-names></name><name><surname>Bindal</surname><given-names>N</given-names></name><name><surname>Boutselakis</surname><given-names>H</given-names></name><name><surname>Ding</surname><given-names>M</given-names></name><name><surname>Bamford</surname><given-names>S</given-names></name><name><surname>Cole</surname><given-names>C</given-names></name><name><surname>Ward</surname><given-names>S</given-names></name><name><surname>Kok</surname><given-names>CY</given-names></name><name><surname>Jia</surname><given-names>M</given-names></name><name><surname>De</surname><given-names>T</given-names></name><name><surname>Teague</surname><given-names>JW</given-names></name><name><surname>Stratton</surname><given-names>MR</given-names></name><name><surname>McDermott</surname><given-names>U</given-names></name><name><surname>Campbell</surname><given-names>PJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>COSMIC: exploring the world's knowledge of somatic mutations in human cancer</article-title><source>Nucleic Acids Research</source><volume>43</volume><fpage>D805</fpage><lpage>D811</lpage><pub-id pub-id-type="doi">10.1093/nar/gku1075</pub-id><pub-id pub-id-type="pmid">25355519</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gray</surname><given-names>LR</given-names></name><name><surname>Tompkins</surname><given-names>SC</given-names></name><name><surname>Taylor</surname><given-names>EB</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Regulation of pyruvate metabolism and human disease</article-title><source>Cellular and Molecular Life Sciences</source><volume>71</volume><fpage>2577</fpage><lpage>2604</lpage><pub-id pub-id-type="doi">10.1007/s00018-013-1539-2</pub-id><pub-id pub-id-type="pmid">24363178</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanahan</surname><given-names>D</given-names></name><name><surname>Weinberg</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Hallmarks of cancer: the next generation</article-title><source>Cell</source><volume>144</volume><fpage>646</fpage><lpage>674</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2011.02.013</pub-id><pub-id pub-id-type="pmid">21376230</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herzig</surname><given-names>S</given-names></name><name><surname>Raemy</surname><given-names>E</given-names></name><name><surname>Montessuit</surname><given-names>S</given-names></name><name><surname>Veuthey</surname><given-names>JL</given-names></name><name><surname>Zamboni</surname><given-names>N</given-names></name><name><surname>Westermann</surname><given-names>B</given-names></name><name><surname>Kunji</surname><given-names>ER</given-names></name><name><surname>Martinou</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Identification and functional expression of the mitochondrial pyruvate carrier</article-title><source>Science</source><volume>337</volume><fpage>93</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1126/science.1218530</pub-id><pub-id pub-id-type="pmid">22628554</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hurlstone</surname><given-names>AF</given-names></name><name><surname>Haramis</surname><given-names>AP</given-names></name><name><surname>Wienholds</surname><given-names>E</given-names></name><name><surname>Begthel</surname><given-names>H</given-names></name><name><surname>Korving</surname><given-names>J</given-names></name><name><surname>Van Eeden</surname><given-names>F</given-names></name><name><surname>Cuppen</surname><given-names>E</given-names></name><name><surname>Zivkovic</surname><given-names>D</given-names></name><name><surname>Plasterk</surname><given-names>RH</given-names></name><name><surname>Clevers</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>The wnt/beta-catenin pathway regulates cardiac valve formation</article-title><source>Nature</source><volume>425</volume><fpage>633</fpage><lpage>637</lpage><pub-id pub-id-type="doi">10.1038/nature02028</pub-id><pub-id pub-id-type="pmid">14534590</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jette</surname><given-names>C</given-names></name><name><surname>Peterson</surname><given-names>PW</given-names></name><name><surname>Sandoval</surname><given-names>IT</given-names></name><name><surname>Manos</surname><given-names>EJ</given-names></name><name><surname>Hadley</surname><given-names>E</given-names></name><name><surname>Ireland</surname><given-names>CM</given-names></name><name><surname>Jones</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>The tumor suppressor adenomatous polyposis coli and caudal related homeodomain protein regulate expression of retinol dehydrogenase L</article-title><source>Journal of Biological Chemistry</source><volume>279</volume><fpage>34397</fpage><lpage>34405</lpage><pub-id pub-id-type="doi">10.1074/jbc.M314021200</pub-id><pub-id pub-id-type="pmid">15190067</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Jung</surname><given-names>WH</given-names></name><name><surname>Koo</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The expression of Glut-1, CAIX, and MCT4 in mucinous carcinoma</article-title><source>Journal of Breast Cancer</source><volume>16</volume><fpage>146</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.4048/jbc.2013.16.2.146</pub-id><pub-id pub-id-type="pmid">23843845</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>W</given-names></name><name><surname>Semenza</surname><given-names>GL</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Pyruvate kinase M2 regulates glucose metabolism by functioning as a coactivator for hypoxia-inducible factor 1 in cancer cells</article-title><source>Oncotarget</source><volume>2</volume><fpage>551</fpage><lpage>556</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.299</pub-id><pub-id pub-id-type="pmid">21709315</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marill</surname><given-names>J</given-names></name><name><surname>Idres</surname><given-names>N</given-names></name><name><surname>Capron</surname><given-names>CC</given-names></name><name><surname>Nguyen</surname><given-names>E</given-names></name><name><surname>Chabot</surname><given-names>GG</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Retinoic acid metabolism and mechanism of action: a review</article-title><source>Current Drug Metabolism</source><volume>4</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.2174/1389200033336900</pub-id><pub-id pub-id-type="pmid">12570742</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McFate</surname><given-names>T</given-names></name><name><surname>Mohyeldin</surname><given-names>A</given-names></name><name><surname>Lu</surname><given-names>H</given-names></name><name><surname>Thakar</surname><given-names>J</given-names></name><name><surname>Henriques</surname><given-names>J</given-names></name><name><surname>Halim</surname><given-names>ND</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Schell</surname><given-names>MJ</given-names></name><name><surname>Tsang</surname><given-names>TM</given-names></name><name><surname>Teahan</surname><given-names>O</given-names></name><name><surname>Zhou</surname><given-names>S</given-names></name><name><surname>Califano</surname><given-names>JA</given-names></name><name><surname>Jeoung</surname><given-names>NH</given-names></name><name><surname>Harris</surname><given-names>RA</given-names></name><name><surname>Verma</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Pyruvate dehydrogenase complex activity controls metabolic and malignant phenotype in cancer cells</article-title><source>Journal of Biological Chemistry</source><volume>283</volume><fpage>22700</fpage><lpage>22708</lpage><pub-id pub-id-type="doi">10.1074/jbc.M801765200</pub-id><pub-id pub-id-type="pmid">18541534</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyoshi</surname><given-names>Y</given-names></name><name><surname>Ando</surname><given-names>H</given-names></name><name><surname>Nagase</surname><given-names>H</given-names></name><name><surname>Nishisho</surname><given-names>I</given-names></name><name><surname>Horii</surname><given-names>A</given-names></name><name><surname>Miki</surname><given-names>Y</given-names></name><name><surname>Mori</surname><given-names>T</given-names></name><name><surname>Utsunomiya</surname><given-names>J</given-names></name><name><surname>Baba</surname><given-names>S</given-names></name><name><surname>Petersen</surname><given-names>G</given-names></name></person-group><year iso-8601-date="1992">1992a</year><article-title>Germ-line mutations of the APC gene in 53 familial adenomatous polyposis patients</article-title><source>PNAS</source><volume>89</volume><fpage>4452</fpage><lpage>4456</lpage><pub-id pub-id-type="doi">10.1073/pnas.89.10.4452</pub-id><pub-id pub-id-type="pmid">1316610</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyoshi</surname><given-names>Y</given-names></name><name><surname>Nagase</surname><given-names>H</given-names></name><name><surname>Ando</surname><given-names>H</given-names></name><name><surname>Horii</surname><given-names>A</given-names></name><name><surname>Ichii</surname><given-names>S</given-names></name><name><surname>Nakatsuru</surname><given-names>S</given-names></name><name><surname>Aoki</surname><given-names>T</given-names></name><name><surname>Miki</surname><given-names>Y</given-names></name><name><surname>Mori</surname><given-names>T</given-names></name><name><surname>Nakamura</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="1992">1992b</year><article-title>Somatic mutations of the APC gene in colorectal tumors: mutation cluster region in the APC gene</article-title><source>Human Molecular Genetics</source><volume>1</volume><fpage>229</fpage><lpage>233</lpage><pub-id pub-id-type="doi">10.1093/hmg/1.4.229</pub-id><pub-id pub-id-type="pmid">1338904</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nadauld</surname><given-names>LD</given-names></name><name><surname>Sandoval</surname><given-names>IT</given-names></name><name><surname>Chidester</surname><given-names>S</given-names></name><name><surname>Yost</surname><given-names>HJ</given-names></name><name><surname>Jones</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Adenomatous polyposis coli control of retinoic acid biosynthesis is critical for zebrafish intestinal development and differentiation</article-title><source>Journal of Biological Chemistry</source><volume>279</volume><fpage>51581</fpage><lpage>51589</lpage><pub-id pub-id-type="doi">10.1074/jbc.M408830200</pub-id><pub-id pub-id-type="pmid">15358764</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nadauld</surname><given-names>LD</given-names></name><name><surname>Shelton</surname><given-names>DN</given-names></name><name><surname>Chidester</surname><given-names>S</given-names></name><name><surname>Yost</surname><given-names>HJ</given-names></name><name><surname>Jones</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>The zebrafish retinol dehydrogenase, rdh1l, is essential for intestinal development and is regulated by the tumor suppressor adenomatous polyposis coli</article-title><source>Journal of Biological Chemistry</source><volume>280</volume><fpage>30490</fpage><lpage>30495</lpage><pub-id pub-id-type="doi">10.1074/jbc.M504973200</pub-id><pub-id pub-id-type="pmid">15967793</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nadauld</surname><given-names>LD</given-names></name><name><surname>Phelps</surname><given-names>R</given-names></name><name><surname>Moore</surname><given-names>BC</given-names></name><name><surname>Eisinger</surname><given-names>A</given-names></name><name><surname>Sandoval</surname><given-names>IT</given-names></name><name><surname>Chidester</surname><given-names>S</given-names></name><name><surname>Peterson</surname><given-names>PW</given-names></name><name><surname>Manos</surname><given-names>EJ</given-names></name><name><surname>Sklow</surname><given-names>B</given-names></name><name><surname>Burt</surname><given-names>RW</given-names></name><name><surname>Jones</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2006">2006a</year><article-title>Adenomatous polyposis coli control of C-terminal binding protein-1 stability regulates expression of intestinal retinol dehydrogenases</article-title><source>Journal of Biological Chemistry</source><volume>281</volume><fpage>37828</fpage><lpage>37835</lpage><pub-id pub-id-type="doi">10.1074/jbc.M602119200</pub-id><pub-id pub-id-type="pmid">17028196</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nadauld</surname><given-names>LD</given-names></name><name><surname>Chidester</surname><given-names>S</given-names></name><name><surname>Shelton</surname><given-names>DN</given-names></name><name><surname>Rai</surname><given-names>K</given-names></name><name><surname>Broadbent</surname><given-names>T</given-names></name><name><surname>Sandoval</surname><given-names>IT</given-names></name><name><surname>Peterson</surname><given-names>PW</given-names></name><name><surname>Manos</surname><given-names>EJ</given-names></name><name><surname>Ireland</surname><given-names>CM</given-names></name><name><surname>Yost</surname><given-names>HJ</given-names></name><name><surname>Jones</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2006">2006b</year><article-title>Dual roles for adenomatous polyposis coli in regulating retinoic acid biosynthesis and wnt during ocular development</article-title><source>PNAS</source><volume>103</volume><fpage>13409</fpage><lpage>13414</lpage><pub-id pub-id-type="doi">10.1073/pnas.0601634103</pub-id><pub-id pub-id-type="pmid">16938888</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neuhauss</surname><given-names>SC</given-names></name><name><surname>Solnica-Krezel</surname><given-names>L</given-names></name><name><surname>Schier</surname><given-names>AF</given-names></name><name><surname>Zwartkruis</surname><given-names>F</given-names></name><name><surname>Stemple</surname><given-names>DL</given-names></name><name><surname>Malicki</surname><given-names>J</given-names></name><name><surname>Abdelilah</surname><given-names>S</given-names></name><name><surname>Stainier</surname><given-names>DY</given-names></name><name><surname>Driever</surname><given-names>W</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Mutations affecting craniofacial development in zebrafish</article-title><source>Development</source><volume>123</volume><fpage>357</fpage><lpage>367</lpage><pub-id pub-id-type="pmid">9007255</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rai</surname><given-names>K</given-names></name><name><surname>Sarkar</surname><given-names>S</given-names></name><name><surname>Broadbent</surname><given-names>TJ</given-names></name><name><surname>Voas</surname><given-names>M</given-names></name><name><surname>Grossmann</surname><given-names>KF</given-names></name><name><surname>Nadauld</surname><given-names>LD</given-names></name><name><surname>Dehghanizadeh</surname><given-names>S</given-names></name><name><surname>Hagos</surname><given-names>FT</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Toth</surname><given-names>RK</given-names></name><name><surname>Chidester</surname><given-names>S</given-names></name><name><surname>Bahr</surname><given-names>TM</given-names></name><name><surname>Johnson</surname><given-names>WE</given-names></name><name><surname>Sklow</surname><given-names>B</given-names></name><name><surname>Burt</surname><given-names>R</given-names></name><name><surname>Cairns</surname><given-names>BR</given-names></name><name><surname>Jones</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>DNA demethylase activity maintains intestinal cells in an undifferentiated state following loss of APC</article-title><source>Cell</source><volume>142</volume><fpage>930</fpage><lpage>942</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2010.08.030</pub-id><pub-id pub-id-type="pmid">20850014</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rong</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>W</given-names></name><name><surname>Ni</surname><given-names>X</given-names></name><name><surname>Kuang</surname><given-names>T</given-names></name><name><surname>Jin</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Lou</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Lactate dehydrogenase A is overexpressed in pancreatic cancer and promotes the growth of pancreatic cancer cells</article-title><source>Tumor Biology</source><volume>34</volume><fpage>1523</fpage><lpage>1530</lpage><pub-id pub-id-type="doi">10.1007/s13277-013-0679-1</pub-id><pub-id pub-id-type="pmid">23404405</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Russo</surname><given-names>JE</given-names></name><name><surname>Hauguitz</surname><given-names>D</given-names></name><name><surname>Hilton</surname><given-names>J</given-names></name></person-group><year iso-8601-date="1988">1988</year><article-title>Inhibition of mouse cytosolic aldehyde dehydrogenase by 4-(diethylamino)benzaldehyde</article-title><source>Biochemical Pharmacology</source><volume>37</volume><fpage>1639</fpage><lpage>1642</lpage><pub-id pub-id-type="doi">10.1016/0006-2952(88)90030-5</pub-id><pub-id pub-id-type="pmid">3358794</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schell</surname><given-names>JC</given-names></name><name><surname>Rutter</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The long and winding road to the mitochondrial pyruvate carrier</article-title><source>Cancer &amp; Metabolism</source><volume>1</volume><fpage>6</fpage><pub-id pub-id-type="doi">10.1186/2049-3002-1-6</pub-id><pub-id pub-id-type="pmid">24280073</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schell</surname><given-names>JC</given-names></name><name><surname>Olson</surname><given-names>KA</given-names></name><name><surname>Jiang</surname><given-names>L</given-names></name><name><surname>Hawkins</surname><given-names>AJ</given-names></name><name><surname>Van Vranken</surname><given-names>JG</given-names></name><name><surname>Xie</surname><given-names>J</given-names></name><name><surname>Egnatchik</surname><given-names>RA</given-names></name><name><surname>Earl</surname><given-names>EG</given-names></name><name><surname>DeBerardinis</surname><given-names>RJ</given-names></name><name><surname>Rutter</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>A role for the mitochondrial pyruvate carrier as a repressor of the warburg effect and colon cancer cell growth</article-title><source>Molecular Cell</source><volume>56</volume><fpage>400</fpage><lpage>413</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2014.09.026</pub-id><pub-id pub-id-type="pmid">25458841</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>J</given-names></name><name><surname>Neu</surname><given-names>K</given-names></name><name><surname>Grimm</surname><given-names>H</given-names></name><name><surname>Velcovsky</surname><given-names>HG</given-names></name><name><surname>Weisse</surname><given-names>G</given-names></name><name><surname>Eigenbrodt</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Tumor M2-pyruvate kinase in lung cancer patients: immunohistochemical detection and disease monitoring</article-title><source>Anticancer Research</source><volume>22</volume><fpage>311</fpage><lpage>318</lpage><pub-id pub-id-type="pmid">12017309</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneikert</surname><given-names>J</given-names></name><name><surname>Behrens</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>The canonical Wnt signalling pathway and its APC partner in colon cancer development</article-title><source>Gut</source><volume>56</volume><fpage>417</fpage><lpage>425</lpage><pub-id pub-id-type="doi">10.1136/gut.2006.093310</pub-id><pub-id pub-id-type="pmid">16840506</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shelton</surname><given-names>DN</given-names></name><name><surname>Sandoval</surname><given-names>IT</given-names></name><name><surname>Eisinger</surname><given-names>A</given-names></name><name><surname>Chidester</surname><given-names>S</given-names></name><name><surname>Ratnayake</surname><given-names>A</given-names></name><name><surname>Ireland</surname><given-names>CM</given-names></name><name><surname>Jones</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Up-regulation of CYP26A1 in adenomatous polyposis coli-deficient vertebrates via a WNT-dependent mechanism: implications for intestinal cell differentiation and colon tumor development</article-title><source>Cancer Research</source><volume>66</volume><fpage>7571</fpage><lpage>7577</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-1067</pub-id><pub-id pub-id-type="pmid">16885356</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sperber</surname><given-names>H</given-names></name><name><surname>Mathieu</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Ferreccio</surname><given-names>A</given-names></name><name><surname>Hesson</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>Z</given-names></name><name><surname>Fischer</surname><given-names>KA</given-names></name><name><surname>Devi</surname><given-names>A</given-names></name><name><surname>Detraux</surname><given-names>D</given-names></name><name><surname>Gu</surname><given-names>H</given-names></name><name><surname>Battle</surname><given-names>SL</given-names></name><name><surname>Showalter</surname><given-names>M</given-names></name><name><surname>Valensisi</surname><given-names>C</given-names></name><name><surname>Bielas</surname><given-names>JH</given-names></name><name><surname>Ericson</surname><given-names>NG</given-names></name><name><surname>Margaretha</surname><given-names>L</given-names></name><name><surname>Robitaille</surname><given-names>AM</given-names></name><name><surname>Margineantu</surname><given-names>D</given-names></name><name><surname>Fiehn</surname><given-names>O</given-names></name><name><surname>Hockenbery</surname><given-names>D</given-names></name><name><surname>Blau</surname><given-names>CA</given-names></name><name><surname>Raftery</surname><given-names>D</given-names></name><name><surname>Margolin</surname><given-names>AA</given-names></name><name><surname>Hawkins</surname><given-names>RD</given-names></name><name><surname>Moon</surname><given-names>RT</given-names></name><name><surname>Ware</surname><given-names>CB</given-names></name><name><surname>Ruohola-Baker</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The metabolome regulates the epigenetic landscape during naive-to-primed human embryonic stem cell transition</article-title><source>Nature Cell Biology</source><volume>17</volume><fpage>1523</fpage><lpage>1535</lpage><pub-id pub-id-type="doi">10.1038/ncb3264</pub-id><pub-id pub-id-type="pmid">26571212</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stackley</surname><given-names>KD</given-names></name><name><surname>Beeson</surname><given-names>CC</given-names></name><name><surname>Rahn</surname><given-names>JJ</given-names></name><name><surname>Chan</surname><given-names>SS</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Bioenergetic profiling of zebrafish embryonic development</article-title><source>PLoS One</source><volume>6</volume><elocation-id>e25652</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0025652</pub-id><pub-id pub-id-type="pmid">21980518</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thisse</surname><given-names>C</given-names></name><name><surname>Thisse</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>High-resolution in situ hybridization to whole-mount zebrafish embryos</article-title><source>Nature Protocols</source><volume>3</volume><fpage>59</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1038/nprot.2007.514</pub-id><pub-id pub-id-type="pmid">18193022</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valvezan</surname><given-names>AJ</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Diehl</surname><given-names>JA</given-names></name><name><surname>Klein</surname><given-names>PS</given-names></name><name><surname>Coli</surname><given-names>AP</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Adenomatous polyposis coli (APC) regulates multiple signaling pathways by enhancing glycogen synthase kinase-3 (GSK-3) activity</article-title><source>Journal of Biological Chemistry</source><volume>287</volume><fpage>3823</fpage><lpage>3832</lpage><pub-id pub-id-type="doi">10.1074/jbc.M111.323337</pub-id><pub-id pub-id-type="pmid">22184111</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vander Heiden</surname><given-names>MG</given-names></name><name><surname>Cantley</surname><given-names>LC</given-names></name><name><surname>Thompson</surname><given-names>CB</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Understanding the warburg effect: the metabolic requirements of cell proliferation</article-title><source>Science</source><volume>324</volume><fpage>1029</fpage><lpage>1033</lpage><pub-id pub-id-type="doi">10.1126/science.1160809</pub-id><pub-id pub-id-type="pmid">19460998</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warburg</surname><given-names>O</given-names></name></person-group><year iso-8601-date="1956">1956</year><article-title>On the origin of cancer cells</article-title><source>Science</source><volume>123</volume><fpage>309</fpage><lpage>314</lpage><pub-id pub-id-type="doi">10.1126/science.123.3191.309</pub-id><pub-id pub-id-type="pmid">13298683</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Westerfield</surname><given-names>M</given-names></name></person-group><year iso-8601-date="1995">1995</year><chapter-title><italic>The Zebrafish Book</italic></chapter-title><edition>3rd Edn</edition><source>A Guide for the Laboratory Use of Zebrafish (Danio Rerio)</source><publisher-loc>Eugene, Oregon</publisher-loc><publisher-name>University of Oregon Press</publisher-name><fpage>385</fpage></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yanes</surname><given-names>O</given-names></name><name><surname>Clark</surname><given-names>J</given-names></name><name><surname>Wong</surname><given-names>DM</given-names></name><name><surname>Patti</surname><given-names>GJ</given-names></name><name><surname>Sánchez-Ruiz</surname><given-names>A</given-names></name><name><surname>Benton</surname><given-names>HP</given-names></name><name><surname>Trauger</surname><given-names>SA</given-names></name><name><surname>Desponts</surname><given-names>C</given-names></name><name><surname>Ding</surname><given-names>S</given-names></name><name><surname>Siuzdak</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Metabolic oxidation regulates embryonic stem cell differentiation</article-title><source>Nature Chemical Biology</source><volume>6</volume><fpage>411</fpage><lpage>417</lpage><pub-id pub-id-type="doi">10.1038/nchembio.364</pub-id><pub-id pub-id-type="pmid">20436487</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yeh</surname><given-names>CS</given-names></name><name><surname>Wang</surname><given-names>JY</given-names></name><name><surname>Chung</surname><given-names>FY</given-names></name><name><surname>Lee</surname><given-names>SC</given-names></name><name><surname>Huang</surname><given-names>MY</given-names></name><name><surname>Kuo</surname><given-names>CW</given-names></name><name><surname>Yang</surname><given-names>MJ</given-names></name><name><surname>Lin</surname><given-names>SR</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Significance of the glycolytic pathway and glycolysis related-genes in tumorigenesis of human colorectal cancers</article-title><source>Oncology Reports</source><volume>19</volume><fpage>81</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.3892/or.19.1.81</pub-id><pub-id pub-id-type="pmid">18097579</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>W</given-names></name><name><surname>Choi</surname><given-names>M</given-names></name><name><surname>Margineantu</surname><given-names>D</given-names></name><name><surname>Margaretha</surname><given-names>L</given-names></name><name><surname>Hesson</surname><given-names>J</given-names></name><name><surname>Cavanaugh</surname><given-names>C</given-names></name><name><surname>Blau</surname><given-names>CA</given-names></name><name><surname>Horwitz</surname><given-names>MS</given-names></name><name><surname>Hockenbery</surname><given-names>D</given-names></name><name><surname>Ware</surname><given-names>C</given-names></name><name><surname>Ruohola-Baker</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>HIF1α induced switch from bivalent to exclusively glycolytic metabolism during ESC-to-EpiSC/hESC transition</article-title><source>The EMBO Journal</source><volume>31</volume><fpage>2103</fpage><lpage>2116</lpage><pub-id pub-id-type="doi">10.1038/emboj.2012.71</pub-id><pub-id pub-id-type="pmid">22446391</pub-id></element-citation></ref></ref-list></back><sub-article article-type="article-commentary" id="SA1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.22706.024</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Krumlauf</surname><given-names>Robb</given-names></name><role>Reviewing editor</role><aff><institution>Stowers Institute for Medical Research</institution>, <country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.</p></boxed-text><p>Thank you for submitting your article &quot;A metabolic switch controls intestinal differentiation downstream of Adenomatous Polyposis Coli (APC)&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by Robb Krumlauf as the Senior Editor and Reviewing Editor. The following individual involved in review of your submission has agreed to reveal their identity: Linheng Li (Reviewer #1).</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>This is an interesting study, using zebrafish as a model, that describes a link between APC and MPC1 expression in the differentiating gut. The data suggests that APC controls the level of MPC1 through the retinoic acid pathway and shows that knockdown of MPC1 recapitulated phenotypes of impaired APC function including failed intestinal differentiation during development. The study provides insight into the role of APC in regulating pyruvate metabolism in intestinal development. Furthermore, these results may be informative for some of the metabolic effects observed on loss of APC in colon cancer. However, there are a number of concerns that need to be addressed to properly support the conclusions made in the paper and facilitate further consideration for publication in <italic>eLife</italic>.</p><p>1) The authors observe that the expression level of several enzymes in the pyruvate pathway are reduced in Apc<sup>mcr</sup> zebrafish, while the expression levels of the same enzymes increase in MPC1 MO model. This observation raises a question of whether the similar phenotypes of MPC1 KD and APC mutation are the result of effects on the same targets. The authors need to comment on this issue.</p><p>2) It is important to show the phenotypes of overexpression MPC1 by injecting mRNA.</p><p>3) Did the authors observe any metabolic switch? What's the change of glycolysis and fatty acid metabolism in Apc<sup>mcr</sup> and MPC1 KD intestines?</p><p>4) In <xref ref-type="fig" rid="fig4">Figure 4</xref>, the authors show that both APC mutant and MPC1 knockdown zebrafish display reduced OCR. To more rigorously claim that impaired mitochondrial function (OCR) in APC mutants is mediated by reduced MPC1 expression, they could show that OCR is rescued in APC mutants when MPC1 is overexpressed (as they did in <xref ref-type="fig" rid="fig3">Figure 3</xref>).</p><p>5) If both APC and MPC1 knockdown lead to defects in mitochondrial function, can they reconcile the gene expression differences in TCA cycle enzymes observed with MPC1 knockdown versus APC mutants (<xref ref-type="fig" rid="fig4">Figure 4</xref> vs. <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>)?</p><p>6) An important control is missing to determine whether MPC2 depletion affects MPC1 expression and vice versa.</p><p>7) The authors suggest that retinoic acid modulates MPC1 expression yet show little evidence besides gene expression changes to connect retinoic acid to APC and MPC1. This could be very indirect. Are retinoic acid levels decreased in APC mutants? Are metabolic defects (OCR) observed in APC mutants rescued by exogenous retinoic acid? The evidence involving retinoic acid is not very strong.</p></body></sub-article><sub-article article-type="reply" id="SA2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.22706.025</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><p><italic>[…] 1) The authors observe that the expression level of several enzymes in the pyruvate pathway are reduced in Apc<sup>mcr</sup> zebrafish, while the expression levels of the same enzymes increase in MPC1 MO model. This observation raises a question of whether the similar phenotypes of MPC1 KD and APC mutation are the result of effects on the same targets. The authors need to comment on this issue.</italic></p><p>We agree this needs discussion and have revised the text to point out that APC has multiple functions. In addition, regulation of the various enzymes downstream of APC could occur in parallel with regulation of MPC1. If this were the case, then knockdown of MPC1 would not necessarily result in changes of the other enzymes. The observed difference, as pointed out by the reviewers, suggests this to be the case.</p><p><italic>2) It is important to show the phenotypes of overexpression MPC1 by injecting mRNA.</italic></p><p>We agree and have provided this as new data in the manuscript (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C</xref>).</p><p><italic>3) Did the authors observe any metabolic switch? What's the change of glycolysis and fatty acid metabolism in Apc<sup>mcr</sup> and MPC1 KD intestines?</italic></p><p>We have observed reduced mitochondrial oxidation and lower triglyceride levels in apc mutants, apc morphants and mpc1 morphants (<xref ref-type="fig" rid="fig4">Figure 4A, B</xref>). As an extension, we have also shown that lactate levels are up in apc mutants (<xref ref-type="fig" rid="fig4">Figure 4E</xref>). We have documented changes in MPC1 levels directly in the intestine by in situ hybridization and observed an intestinal-specific phenotype by knockdown of MPC1 (<xref ref-type="fig" rid="fig1">Figure 1C, 1D</xref>, <xref ref-type="fig" rid="fig2">2B, 2C</xref>).</p><p><italic>4) In <xref ref-type="fig" rid="fig4">Figure 4</xref>, the authors show that both APC mutant and MPC1 knockdown zebrafish display reduced OCR. To more rigorously claim that impaired mitochondrial function (OCR) in APC mutants is mediated by reduced MPC1 expression, they could show that OCR is rescued in APC mutants when MPC1 is overexpressed (as they did in <xref ref-type="fig" rid="fig3">Figure 3</xref>).</italic></p><p>We have performed the requested rescue experiment and have shown that lactate levels are significantly reduced in apc mutants overexpressing MPC1 (<xref ref-type="fig" rid="fig4">Figure 4E</xref>). We used lactate as a second marker for increased anaerobic glycolysis. This again is consistent with a role for MPC1 downstream of APC.</p><p><italic>5) If both APC and MPC1 knockdown lead to defects in mitochondrial function, can they reconcile the gene expression differences in TCA cycle enzymes observed with MPC1 knockdown versus APC mutants (<xref ref-type="fig" rid="fig4">Figure 4</xref> vs. <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>)?</italic></p><p>This is a similar point as number #1 above. Although we think MPC1 and other TCA cycle enzymes are downstream of APC, our data suggest that they are regulated in parallel. MPC1 knockdown alone does not therefore, recapitulate this result.</p><p><italic>6) An important control is missing to determine whether MPC2 depletion affects MPC1 expression and vice versa.</italic></p><p>We have done this experiment and knockout of MPC2 does not affect levels of MPC1 (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1C</xref>).</p><p><italic>7) The authors suggest that retinoic acid modulates MPC1 expression yet show little evidence besides gene expression changes to connect retinoic acid to APC and MPC1. This could be very indirect. Are retinoic acid levels decreased in APC mutants? Are metabolic defects (OCR) observed in APC mutants rescued by exogenous retinoic acid? The evidence involving retinoic acid is not very strong.</italic></p><p>A major focus of our lab over the past 12 years is the role of retinoic acid downstream of APC in each of the phenotypes described here (Jette 2004, Nadauld 2004, Nadauld 2005, Nadauld 2006, Rai 2010). Our findings are documented in 12 published manuscripts that illustrated that many of the defects in apc mutant fish, including intestinal differentiation, result from the lack of RA synthesis. This process is controlled mechanistically by CTBP1. We have revised the text to make this point more clear. Although we have firmly established an epistatic role for RA downstream of APC in our previous work, the specific direct functions of RA remain unclear. Our key recent finding suggests that RA effects are indeed indirect by controlling the remodeling of the epigenetic landscape to allow differentiation (Rai 2010). Here we are demonstrating again an epistatic relationship of MPC1 downstream of RA. We have now addressed the direct versus indirect question raised by the reviewers by treating 72 hpf apc mutants with RA. At this time point, we do not observe an immediate induction of MPC1. RA rescue experiments are difficult to perform as RA itself has a profound effect on the development of the embryo overall. We, therefore, rely on RA deficiency experiments to place MPC1 downstream of RA. In this case, blockade of RA synthesis caused phenotypes similar to loss of APC and leads to reduced levels of MPC1. We have revised the manuscript to emphasize the likely indirect regulation of MPC1 by RA.</p></body></sub-article></article>